[PubMed](#)[Nucleotide](#)[Protein](#)[Genome](#)[Structure](#)[PopSet](#)[Taxonomy](#)[OMIM](#)[Bc](#)Search for ☒ Limits[Preview/Index](#)[History](#)[Clipboard](#)[Details](#)[About Entrez](#)[Display](#)[Abstract](#)[Sort](#)[Save](#)[Text](#)[Clip Add](#)[Order](#)[Text Version](#)[Entrez PubMed](#)[Overview](#)[Help | FAQ](#)[Tutorial](#)[New/Noteworthy](#)[E-Utilities](#)[PubMed Services](#)[Journal Browser](#)[MeSH Browser](#)[Single Citation Matcher](#)[Batch Citation Matcher](#)[Clinical Queries](#)[LinkOut](#)[Cubby](#)[Related Resources](#)[Order Documents](#)[NLM Gateway](#)[TOXNET](#)[Consumer Health](#)[Clinical Alerts](#)[ClinicalTrials.gov](#)[PubMed Central](#)[Privacy Policy](#)☐ 1: Cancer Treat Rev 2001 Aug;27(4):247-55[Related Articles, Books, LinkOut](#)**ELSEVIER SCIENCE  
FULL-TEXT ARTICLE**

## Dendritic cell vaccines for cancer therapy.

**Sprinzi GM, Kacani L, Schrott-Fischer A, Romani N, Thumfart WF.**

Department of Otorhinolaryngology, Head and Neck Surgery, University of Innsbruck, Austria. georg.sprinzi@uibk.ac.at

Dendritic cells (DC) are professional antigen-presenting cells whose primary function is the initiation of immune response. Based on the finding that the immune system usually fails to identify and kill cancer cells, DC have been recently used as vaccines for stimulation of tumour-specific immunity. This review focuses on pitfalls related to DC-based vaccination against solid tumours and on improvement of this immunotherapeutic approach for routine treatment of cancer disease. Copyright 2001 Harcourt Publishers Ltd.


**Publication Types:**

- Review
- Review, Tutorial

PMID: 11545544 [PubMed - indexed for MEDLINE]

[Display](#)[Abstract](#)[Sort](#)[Save](#)[Text](#)[Clip Add](#)[Order](#)[Write to the Help Desk](#)[NCBI | NLM | NIH](#)[Department of Health & Human Services](#)[Freedom of Information Act | Disclaimer](#)

i686-pc-linux-gnu Jun 12 2002 10:20:00

[PubMed](#)[Nucleotide](#)[Protein](#)[Genome](#)[Structure](#)[PopSet](#)[Taxonomy](#)[OMIM](#)[Bc](#)Search for [Limits](#)[Preview/Index](#)[History](#)[Clipboard](#)[Details](#)[About Entrez](#)[Display](#)[Abstract](#)[Sort](#)[Save](#)[Text](#)[Clip Add](#)[Order](#)[Text Version](#)[Entrez PubMed](#)[Overview](#)[Help | FAQ](#)[Tutorial](#)[New/Noteworthy](#)[E-Utilities](#)[PubMed Services](#)[Journal Browser](#)[MeSH Browser](#)[Single Citation Matcher](#)[Batch Citation Matcher](#)[Clinical Queries](#)[LinkOut](#)[Cubby](#)[Related Resources](#)[Order Documents](#)[NLM Gateway](#)[TOXNET](#)[Consumer Health](#)[Clinical Alerts](#)[ClinicalTrials.gov](#)[PubMed Central](#)[Privacy Policy](#)☐ 1: Cancer Gene Ther 1996 Jul-Aug;3(4):221-9[Related Articles, Books, LinkOut](#)

## **Tumor inhibitory activity of anti-ras ribozymes delivered by retroviral gene transfer.**

**Li M, Lonial H, Citarella R, Lindh D, Colina L, Kramer R.**


Department of Oncology and Immunology, Wyeth-Ayerst Research, Pearl River, NY 10965, USA.

This study reports the successful introduction into tumor cells of a ribozyme directed against an oncogene using a retroviral gene delivery system. A hammerhead ribozyme that selectively targets and cleaves the activated Ha-ras (V12Ras) oncogene was delivered using a retroviral vector and expressed under the control of a transfer RNA promoter in V12Ras-transformed 3T3 murine fibroblast and rat colon epithelial cells. The expression of V12Ras messenger RNA and V12Ras P21 protein was reduced by up to 100% and 75%, respectively, in cells transduced with functional ribozyme. Reductions in V12Ras expression correlated with the stable expression of the functional ribozyme in vivo and decreased tumorigenicity in nude mice. Ribozyme constructs containing identical antisense flanking regions, but a mutant catalytic center, did not attenuate V12Ras expression or decrease the tumorigenicity of transduced tumor cells. These data support the potential therapeutic role of antioncogene ribozymes.

PMID: 8853546 [PubMed - indexed for MEDLINE]

[Display](#)[Abstract](#)[Sort](#)[Save](#)[Text](#)[Clip Add](#)[Order](#)[Write to the Help Desk](#)[NCBI | NLM | NIH](#)[Department of Health & Human Services](#)[Freedom of Information Act | Disclaimer](#)

i686-pc-linux-gnu Jun 12 2002 10:20:00

[PubMed](#)[Nucleotide](#)[Protein](#)[Genome](#)[Structure](#)[PopSet](#)[Taxonomy](#)[OMIM](#)[Bc](#)

Search



for

[Limits](#)[Preview/Index](#)[History](#)[Clipboard](#)[Details](#)[About Entrez](#)[Display](#)[Abstract](#)[Sort](#)[Save](#)[Text](#)[Clip Add](#)[Order](#)[Text Version](#)[Entrez PubMed](#)[Overview](#)[Help | FAQ](#)[Tutorial](#)[New/Noteworthy](#)[E-Utilities](#)[PubMed Services](#)[Journal Browser](#)[MeSH Browser](#)[Single Citation Matcher](#)[Batch Citation Matcher](#)[Clinical Queries](#)[LinkOut](#)[Cubby](#)[Related Resources](#)[Order Documents](#)[NLM Gateway](#)[TOXNET](#)[Consumer Health](#)[Clinical Alerts](#)[ClinicalTrials.gov](#)[PubMed Central](#)[Privacy Policy](#)☐ 1: Mutat Res 1988 Jun;199(2):341-51[Related Articles, Books, LinkOut](#)

## Transformation of diploid human fibroblasts by transfection with the v-sis, PDGF2/c-sis, or T24 H-ras genes.

Fry DG, Hurlin PJ, Maher VM, McCormick JJ.

Fee Hall, Department of Microbiology, Michigan State University, East Lansing 48824-1316.

Gene transfection techniques have provided powerful methods to examine the roles of cellular and retroviral oncogenes in the transformation process in rodent fibroblasts. However, the use of such techniques with diploid human fibroblasts has been limited. We have developed transfection procedures to reproducibly transfect such cells with oncogenes, and methods for the biological characterization of the transformants. We have shown that the v-sis and T24 H-ras oncogenes, as well as the platelet-derived growth factor gene (PDGF2/c-sis), are capable of inducing a transformed phenotype in normal diploid human fibroblasts, but are not capable of conferring infinite lifespan or making such cells tumorigenic.

PMID: 3287149 [PubMed - indexed for MEDLINE]

[Display](#)[Abstract](#)[Sort](#)[Save](#)[Text](#)[Clip Add](#)[Order](#)[Write to the Help Desk](#)[NCBI | NLM | NIH](#)[Department of Health & Human Services](#)[Freedom of Information Act | Disclaimer](#)

i686-pc-linux-gnu Jun 12 2002 10:20:00

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptl642cxy

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\*\*\*\*\* Welcome to STN International \*\*\*\*\*

NEWS 1 Web page URIs for STN Seminar Schedule - N. America  
NEWS 2 BLAST(R) searching in REGISTRY available in STN on the Web  
NEWS 3 Jan 25 FSTA has been reloaded and moves to weekly updates  
NEWS 4 Feb 01 DKLIT now produced by FIZ Karlsruhe and has a new update  
NEWS 5 Feb 19 Access via Tymnet and SprintNet Eliminated Effective 3/31/02  
NEWS 6 Mar 08 Gene Names now available in BIOSIS  
NEWS 7 Mar 22 TOXIT no longer available  
NEWS 8 Mar 22 TRCBERMO no longer available  
NEWS 9 Mar 28 US Provisional Priorities searched with P in CA/CAPUS  
and USPATFULL  
NEWS 10 Mar 28 LIPNST/CAIC added for property searching in REGISTRY  
NEWS 11 Apr 02 PAPERCHM no longer available on STN. Use PAPERCHM2 instead.  
NEWS 12 Apr 08 "Ask CAS" for self-help around the clock  
NEWS 13 Apr 09 BELSTEIN: Reload and implementation of a New Subject Area  
NEWS 14 Apr 09 ZDB will be removed from STN  
NEWS 15 Apr 19 US Patent Applications available in IPICDB, IPIPAT, and IFIUDB  
NEWS 16 Apr 22 Records from IP.com available in CAPUS, HCAPUS, and ZCAPUS  
NEWS 17 Apr 22 BIOSIS Gene Names now available in TOXCENTER  
NEWS 18 Apr 22 Federal Research in Progress (FEDRIP) now available  
NEWS 19 Jun 03 New e-mail delivery for search results now available  
NEWS 20 Jun 10 MEDLINE Reload  
NEWS 21 Jun 10 PCTFULL has been reloaded  
NEWS 22 Jul 02 FOREGE no longer contains STANDARDS file segment

NEWS EXPRESS February 1 CURRENT WINDOWS VERSION IS V6.0d.  
CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.03a(JP).  
AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\*\*\*\*\* STN Columbus \*\*\*\*\*

FILE 'HOME' ENTERED AT 09:10:35 ON 11 JUL 2002

=> file medline, cancerlit, caplus, uspatfull, biosis, embase, confsci  
COST IN U.S. DOLLARS  
FULL ESTIMATED COST  
0.21

FILE 'MEDLINE' ENTERED AT 09:11:14 ON 11 JUL 2002  
FILE 'CANCERLIT' ENTERED AT 09:11:14 ON 11 JUL 2002

FILE 'CAPLUS' ENTERED AT 09:11:14 ON 11 JUL 2002  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 09:11:14 ON 11 JUL 2002  
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)  
FILE 'BIOSIS' ENTERED AT 09:11:14 ON 11 JUL 2002  
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'EMBASE' ENTERED AT 09:11:14 ON 11 JUL 2002  
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.  
FILE 'CONFSCI' ENTERED AT 09:11:14 ON 11 JUL 2002  
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

=> s immunogen? (s) transgene?  
L1 538 IMMUNOGEN? (S) TRANSGENE?

=> s 11 and alligen?  
L2 52 L1 AND ALILOGEN?

=> s 12 and promot?  
L3 27 L2 AND PROMOT?

=> s 13 not py>1998  
L4 '1998' NOT A VALID FIELD CODE  
11 L3 NOT PY>1998

=> d 14 1-11

L4 ANSWER 1 OF 11 USPATFULL  
AN 1998:138874 USPATFULL  
TI Adeno-associated viral (AAV) liposomes and methods related thereto  
IN Philip, Ramilla, Redwood City, CA, United States  
Lebkowski, Jane, Portola Valley, CA, United States  
PA Rhone-Poulenc Rorer Pharmaceuticals Inc., Collegeville, PA, United States (U.S. corporation)  
PI US 5834441 19981110  
AT US 1994-305221 19940912 (B)  
RUI Continuation-in-part of Ser. No. US 1993-120605, filed on 13 Sep 1993,  
now abandoned  
DT Utility  
FS Granted  
IN.CNT 2059

INCLM: 514/044.000

INCLS: 424/093.210; 424/450.000; 435/069.100; 435/172.300; 435/320.100;  
435/325.000; 536/024.100; 935/022.000; 935/034.000; 935/056.000;  
935/060.000; 935/062.000; 935/070.000

NCLM: 514/044.000

NCLS: 424/093.210; 424/450.000; 435/069.100; 435/320.100; 435/325.000;  
435/458.000; 536/024.100

IC [6]  
ICM: A01N063-00

ICS: A61K048-00; A61K009-127; C12N005-00  
 514/42; 514/72; 435/320.1; 435/235.1; 435/172.3; 435/240.2; 435/69.1;  
 435/325; 424/79.1; 424/93.21; 424/450; 536/24.1; 935/22; 935/34; 935/56;  
 935/60; 935/62; 935/70  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 2 OF 11 USPTAFULL  
 AN 1998:118845 USPTAFULL  
 TI Transgenic non-human animals for producing heterologous antibodies  
 IN Lomborg, Nils, San Francisco, CA, United States  
 PA Key, Robert M., San Francisco, CA, United States  
 PA Genpharm International Inc., Palo Alto, CA, United States (U.S. corporation)  
 PI US 5814318 19980929  
 AI US 1993-96762 19930722 (8)  
 RLI Continuation-in-part of Ser. No. US 1993-53131, filed on 26 Apr 1993, now patented, Pat. No. US 5661016 which is a continuation-in-part of Ser. No. US 1992-990860, filed on 16 Dec 1992, now patented, Pat. No. US 5545806 which is a continuation-in-part of Ser. No. US 1992-904068, filed on 23 Jun 1992 which is a continuation-in-part of Ser. No. US 1992-853408, filed on 18 Mar 1992 which is a continuation-in-part of Ser. No. US 1991-810279, filed on 17 Dec 1991, now patented, Pat. No. US 5569825 which is a continuation-in-part of Ser. No. US 1990-575962, filed on 31 Aug 1990, now abandoned which is a continuation-in-part of Ser. No. US 1990-574748, filed on 29 Aug 1990, now abandoned

DT Utility  
 PS Granted  
 LN CNT 7909  
 INCL INCLM: 424/184.100  
 INCLS: 800/002.000; 435/172.300; 536/023.100; 536/023.530; 530/387.100  
 NCLM: 424/184.100  
 NCLS: 435/069.600; 530/387.100; 536/023.100; 536/023.530; 800/006.000  
 IC [6]  
 ICM: C12N015-00  
 ICS: A61K039-00; C07K016-00; C07H021-04  
 EXP 800/2; 435/172.3; 424/184.1  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 3 OF 11 USPTAFULL  
 AN 1998:92262 USPTAFULL  
 TI Transgenic non-human animals for producing heterologous antibodies  
 IN Lomborg, Nils, San Francisco, CA, United States  
 PA Key, Robert M., San Francisco, CA, United States  
 PA Genpharm International, Inc., Palo Alto, CA, United States (U.S. corporation)  
 PI US 5789650 19980804  
 AI US 1992-853408 19920318 (7)  
 RLI Continuation-in-part of Ser. No. US 1992-834539, filed on 5 Feb 1992, now patented, Pat. No. US 563425 which is a continuation-in-part of Ser. No. US 1991-810279, filed on 17 Dec 1991, now patented, Pat. No. US 5569825 which is a continuation-in-part of Ser. No. US 1990-575962, filed on 30 Sep 1990, now abandoned which is a continuation-in-part of Ser. No. US 1990-574748, filed on 29 Aug 1990, now abandoned

PRAI WO 1991-US6185 19910828  
 WO 1991-US6185 19910828  
 DT Utility  
 PS Granted  
 LN CNT 5073  
 INCL INCLM: 800/002.000  
 INCLS: 435/172.300; 530/387.100; 536/026.530; 800/DIG.001; 800/DIG.002;  
 NCLM: 800/DIG.004  
 NCLS: 800/018.000  
 IC [6]  
 ICM: 530/387.100  
 ICM: C12N015-00

ICS: C07K016-00; C07H019-04  
 800/2; 536/23.52  
 EXP 800/2; 435/172.2; 435/240.270; 435/240.260; 435/069.100;  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 4 OF 11 USPTAFULL  
 AN 1998:72461 USPTAFULL  
 TI Transgenic non-human animals capable of producing heterologous antibodies  
 IN Lomborg, Nils, Redwood City, CA, United States  
 PA Key, Robert M., San Francisco, CA, United States  
 PA Genpharm International, Inc., Palo Alto, CA, United States (U.S. corporation)  
 PI US 5770429 19980623  
 AI US 1995-544404 19951010 (8)  
 RLI Continuation-in-part of Ser. No. US 1994-352322, filed on 7 Dec 1994, now patented, Pat. No. US 5625126 which is a continuation-in-part of Ser. No. US 1994-209741, filed on 9 Mar 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-165699, filed on 10 Dec 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-161739, filed on 3 Dec 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-155301, filed on 15 Nov 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-96762, filed on 22 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-53131, filed on 26 Apr 1993, now patented, Pat. No. US 5661016 which is a continuation-in-part of Ser. No. US 1992-990860, filed on 16 Dec 1992, now patented, Pat. No. US 5545806 which is a continuation-in-part of Ser. No. US 1992-904068, filed on 23 Jun 1992 which is a continuation-in-part of Ser. No. US 1992-853408, filed on 18 Mar 1992 which is a continuation-in-part of Ser. No. US 1991-810279, filed on 17 Dec 1991, now patented, Pat. No. US 5569825 which is a continuation-in-part of Ser. No. US 1990-575962, filed on 31 Aug 1990, now abandoned which is a continuation-in-part of Ser. No. US 1990-574748, filed on 29 Aug 1990, now abandoned

PRAI WO 1991-US6185 19910828  
 WO 1992-US10983 19921217  
 WO 1994-US4580 19940425  
 DT Utility  
 PS Granted  
 LN CNT 8550  
 INCL INCLM: 435/240.200  
 INCLS: 530/387.100; 530/388.100; 530/388.150; 530/388.200; 800/002.000; 800/DIG.001; 424/184.100; 435/240.270; 435/240.260; 435/069.100;  
 NCLM: 435/328.000  
 NCLS: 424/184.100; 435/069.100; 435/332.000; 435/343.200; 530/387.100; 530/388.100; 530/388.150; 530/388.200; 536/023.100; 536/023.530; 800/006.000  
 IC [6]  
 ICM: A61K039-00  
 ICS: C12N005-00; C12N015-00; C12P021-06; C07K016-00  
 EXP 800/2; 435/172.2; 435/240.277; 424/184.1; 530/350; 530/387.1  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 5 OF 11 USPTAFULL  
 AN 97:76001 USPTAFULL  
 TI Transgenic non-human animals capable of producing heterologous antibodies of various isotypes  
 IN Lomborg, Nils, San Francisco, CA, United States  
 PA Key, Robert M., San Francisco, CA, United States  
 PA Genpharm International Inc., Palo Alto, CA, United States (U.S. corporation)  
 PI US 5661016 19970826  
 AI US 1993-53131 19930426 (8)  
 RLI Continuation-in-part of Ser. No. US 1992-990860, filed on 16 Dec 1992,

now patented, Pat. No. US 5454806 which is a continuation-in-part of Ser. No. US 1992-904068, filed on 23 Jun 1992 which is a continuation-in-part of Ser. No. US 1992-853408, filed on 18 Mar 1992 which is a continuation-in-part of Ser. No. US 1992-834539, filed on 5 Feb 1992 which is a continuation-in-part of Ser. No. US 1991-810279, filed on 17 Dec 1991, now patented, Pat. No. US 5569825 which is a continuation-in-part of Ser. No. US 1990-575962, filed on 31 Aug 1990, now abandoned which is a continuation-in-part of Ser. No. US 1990-574748, filed on 29 Aug 1990, now abandoned

MO 1991-US9206185 19910828  
MO 1992-US10983 19921217

DT Utility  
FS Granted  
LN.CNT 5602  
INCL INCLM: 435/172.300  
INCLS: 424/184.100; 435/091.100; 435/172.100; 530/387.100; 536/023.100; 536/023.530; 800/002.000; 935/019.000; 935/089.000; 935/093.000; 935/103.000

NCL NCLM: 435/452.000  
NCLS: 424/184.100; 435/091.100; 530/387.100; 536/023.100; 536/023.530

IC [6]  
ICM: C12N015-00  
ICS: A61K039-00; C12P019-34; C07K016-00  
800/2; 435/172.2; 435/240.2; 530/388.1

EXP CAS INDEXING IS AVAILABLE FOR THIS PATENT.

LA ANSWER 6 OF 11 USPTAFULL  
97.36385 USPTAFULL

AN Transgenic non-human animals for producing heterologous antibodies  
TI Lomborg, Nils, Redwood City, CA, United States  
IN Kay, Robert M., San Francisco, CA, United States  
PA Genpharm International, Inc., Palo Alto, CA, United States (U.S. corporation)

PI US 5625126 19970429  
AI US 1994-352322 19941207 (8)  
RLI Continuation-in-part of Ser. No. US 1994-209741, filed on 9 Mar 1994 which is a continuation-in-part of Ser. No. US 1993-165699, filed on 10 Dec 1993 which is a continuation-in-part of Ser. No. US 1993-161739, filed on 3 Dec 1993 which is a continuation-in-part of Ser. No. US 1993-155301, filed on 18 Nov 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-96762, filed on 22 Jul 1993 which is a continuation-in-part of Ser. No. US 1993-53131, filed on 26 Apr 1993 which is a continuation-in-part of Ser. No. US 1992-990860, filed on 16 Dec 1992, now patented, Pat. No. US 5545806 which is a continuation-in-part of Ser. No. US 1992-904068, filed on 23 Jun 1992 which is a continuation-in-part of Ser. No. US 1992-853408, filed on 18 Mar 1992 which is a continuation-in-part of Ser. No. US 1992-834539, filed on 5 Feb 1992, now patented, Pat. No. US 5633425 which is a continuation-in-part of Ser. No. US 1991-810279, filed on 17 Dec 1991, now patented, Pat. No. US 5569825 which is a continuation-in-part of Ser. No. US 1990-575962, filed on 31 Aug 1990, now abandoned which is a continuation-in-part of Ser. No. US 1990-574748, filed on 29 Aug 1990, now abandoned

DT Utility  
FS Granted  
LN.CNT 7534  
INCL INCLM: 800/002.000  
INCLS: 435/172.300; 536/023.100; 536/023.500; 536/023.530; 800/DIG.001; 800/DIG.004

NCL NCLM: 800/018.000  
NCLS: 536/023.100; 536/023.500; 536/023.530

IC [6]  
ICM: C12N015-00  
ICS: C07H021-02; C07H021-04

EXP 800/2; 435/172.3; 435/172.2; 536/23.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

LA ANSWER 7 OF 11 USPTAFULL  
97.1394 USPTAFULL

AN Transgenic mice depleted in a mature lymphocytic cell-type  
TI Krangelort, Paulus J. A., Amsterdam, Netherlands  
IN Berns, Antonius J. M., Spaarndam, Netherlands  
PA Genpharm International, Inc., Palo Alto, CA, United States (U.S. corporation)

PI US 5591669 19970107  
AI US 1995-454034 19950530 (8)  
RLI Continuation of Ser. No. US 1992-919936, filed on 27 Jul 1992, now patented, Pat. No. US 5434340 which is a continuation of Ser. No. US 1988-280218, filed on 5 Dec 1988, now patented, Pat. No. US 5175384

DT Utility  
FS Granted  
LN.CNT 1599  
INCL INCLM: 800/002.000  
INCLS: 800/DIG.001; 435/172.300; 935/111.000

NCL NCLM: 800/011.000  
NCLS: 800/018.000

IC [6]  
ICM: C12N015-00  
800/2; 800/DIG.1; 800/DIG.2; 800/DIG.3; 435/172.3; 435/320.1; 435/317.1; 935/111

EXP CAS INDEXING IS AVAILABLE FOR THIS PATENT.

LA ANSWER 8 OF 11 USPTAFULL  
96.99376 USPTAFULL

AN Transgenic non-human animals capable of producing heterologous antibodies of various isotypes  
TI Lomborg, Nils, San Francisco, CA, United States  
IN Kay, Robert M., San Francisco, CA, United States  
PA Genpharm International, Mountain View, CA, United States (U.S. corporation)

PI US 5569825 19961029  
AI US 1991-810279 19911217 (7)  
RLI Continuation-in-part of Ser. No. US 1990-575962, filed on 31 Aug 1990, now abandoned which is a continuation-in-part of Ser. No. US 1990-574748, filed on 29 Aug 1990, now abandoned

DT Utility  
FS Granted  
LN.CNT 3377  
INCL INCLM: 800/002.000  
INCLS: 435/172.300; 435/320.100; 536/023.530; 800/DIG.001

NCL NCLM: 800/018.000  
NCLS: 435/320.100; 536/023.530

IC [6]  
ICM: C12N015-00  
ICS: C07H021-04  
800/2; 536/23.53

EXP CAS INDEXING IS AVAILABLE FOR THIS PATENT.

LA ANSWER 9 OF 11 USPTAFULL  
96.73050 USPTAFULL

AN Transgenic non-human animals for producing heterologous antibodies  
TI Lomborg, Nils, San Francisco, CA, United States  
IN Kay, Robert M., San Francisco, CA, United States  
PA Genpharm International, Inc., Mountain View, CA, United States (U.S. corporation)

PI US 5545806 19960813  
AI US 1992-990860 19921216 (7)  
RLI Continuation-in-part of Ser. No. US 1991-810279, filed on 17 Dec 1991 And a continuation-in-part of Ser. No. US 1992-904068, filed on 23 Jun

1992 which is a continuation-in-part of Ser. No. US 1992-853408, filed on 18 Mar 1992 which is a continuation-in-part of Ser. No. US 1990-575962, filed on 31 Aug 1990, now abandoned which is a continuation-in-part of Ser. No. US 1990-574748, filed on 29 Aug 1990, now abandoned

Utility  
Granted

LN CNT 4576

INCL INCLM: 800/002.000  
INCLS: 800/DIG.001; 800/DIG.004; 536/023.530; 536/023.100;  
424/184.100; 435/172.300; 435/320.100  
NCLM: 800/006.000  
NCLS: 424/184.100; 435/069.600; 435/320.100; 536/023.100; 536/023.500;  
536/023.530; 800/018.000

IC [6]  
ICM: C12N015-00  
ICS: C07H021-64; A61K039-00  
800/2; 424/85.7; 424/184.1; 536/23.53; 435/172.3  
EXF 800/2; 424/85.7; 424/184.1; 536/23.53; 435/172.3  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 10 OF 11 USPATFULL  
AN 95:65107 USPATFULL  
TI Transgenic mice depleted in mature T-cells and methods for making  
IN Transgenic mice  
Krimpenfort, Paulus J. A., Amsterdam, Netherlands  
Berns, Antonius J. M., Spaarndam, Netherlands  
GenPharm International, Inc., Mountain View, CA, United States (U.S. corporation)  
PI US 5434340 19950718  
AI US 1992-919936 19920727 (7)  
RLI Continuation of Ser. No. US 1988-280218, filed on 5 Dec 1988, now patented, Pat. No. US 5175384  
DT Utility  
FS Granted  
LN CNT 1598

INCL INCLM: 800/002.000  
INCLS: 800/DIG.001; 435/172.300; 935/111.000  
NCLM: 800/011.000  
NCLS: 800/018.000; 800/023.000; 800/025.000

IC [6]  
ICM: C12N015-00  
800/2; 800/DIG.2; 800/DIG.1; 800/DIG.3; 435/172.3; 435/320.1; 435/317.1;  
935/111

EXF 800/2; 800/DIG.2; 800/DIG.1; 800/DIG.3; 435/172.3; 435/320.1; 435/317.1;  
935/111

L4 ANSWER 11 OF 11 USPATFULL  
AN 92:107045 USPATFULL  
TI Transgenic mice depleted in mature T-cells and methods for making  
IN Transgenic mice  
Krimpenfort, Paulus J. A., Amsterdam, Netherlands  
Berns, Antonius J. M., Spaarndam, Netherlands  
GenPharm International, Mountain View, CA, United States (U.S. corporation)  
PI US 5175384 19921229  
AI US 1988-280218 19881205 (7)  
DT Utility  
FS Granted  
LN CNT 1517

INCL INCLM: 800/002.000  
INCLS: 800/DIG.001; 435/172.300; 935/111.000  
NCLM: 800/011.000  
NCLS: 800/018.000; 800/023.000

IC [5]  
ICM: C12N015-00  
435/172.3; 800/2; 800/DIG.1-DIG.3; 935/111

=> d his  
(FILE 'HOME' ENTERED AT 09:10:35 ON 11 JUL 2002)

FILE 'MEDLINE, CANCERLIT, CAPLUS, USPATFULL, BIOSIS, EMBASE, CONFSCI'  
ENTERED AT 09:11:14 ON 11 JUL 2002

L1 538 S IMMUNOGEN? (S) TRANSGENE?  
L2 52 S L1 AND ALLOGEN?  
L3 27 S L2 AND PROMOT?  
L4 11 S L3 NOT PY>1998

=> 6 L2 and cell? (A) therap?  
2 FILES SEARCHED...  
L5 6 FILES SEARCHED...  
L6 1 L2 AND CELL? (A) THERAP?

=> d 15

L5 ANSWER 1 OF 1 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
AN 2002:220521 BIOSIS  
DN PREV200200220521  
TI Evaluation of a novel suicide gene for T cell therapy.  
AU Berger, Carolina (1); Blau, C. Anthony; Heimfeld, Shelly; Dalgarno, David; Clackson, Tim; Riddell, Stanley R. (1)  
CS (1) Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA USA  
SO Blood, (November 16, 2001) Vol. 98, No. 11 Part 1, pp. 694a.  
http://www.bloodjournal.org/. print.  
Meeting Info.: 43rd Annual Meeting of the American Society of Hematology, Part 1 Orlando, Florida, USA December 07-11, 2001  
ISSN: 0006-4971.

DT Conference  
LA English

=> d his  
(FILE 'HOME' ENTERED AT 09:10:35 ON 11 JUL 2002)

FILE 'MEDLINE, CANCERLIT, CAPLUS, USPATFULL, BIOSIS, EMBASE, CONFSCI'  
ENTERED AT 09:11:14 ON 11 JUL 2002

L1 538 S IMMUNOGEN? (S) TRANSGENE?  
L2 52 S L1 AND ALLOGEN?  
L3 27 S L2 AND PROMOT?  
L4 11 S L3 NOT PY>1998

=> s 11 and cell? (A) vaccine  
2 FILES SEARCHED...  
L6 6 FILES SEARCHED...  
L7 12 L1 AND CELL? (A) VACCINE

=> d 16 1-12

L6 ANSWER 1 OF 12 MEDLINE  
AN 2001454053 MEDLINE  
DN 21390644 Pubmed ID: 11499806  
TI Comparative analysis of IFN-gamma B7.1 and antisense TGF-beta gene transfer on the tumorigenicity of a poorly immunogenic metastatic mammary carcinoma.  
AU Wu R S; Koble J J; Besselsen D G; Fong T C; Mack V D; McFarthern J A; Aponte-Roy E T

CS Department of Microbiology, Hayward, CA 94545, USA.  
 NC CA6929-01A (NCI)  
 SO CANCER IMMUNOLOGY, IMMUNOTHERAPY, (2001 Jul) 50 (5) 229-40.  
 Journal code: 8605732. ISSN: 0340-7004.  
 CY Germany: Germany, Federal Republic of  
 DT Journal: Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 200108  
 ED Entered STN: 20010814  
 Last updated on STN: 20010903  
 Entered Medline: 20010830

L6 ANSWER 2 OF 12 MEDLINE  
 AN 1998073914  
 DN 98073914 PubMed ID: 9409449  
 TI Construction and characterization of retroviral vectors for interleukin-2 gene therapy.  
 AU Fakhrai H; Shawler D L; Van Beveren C; Lin H; Dorigo O; Solomon M J; Gjerstet R A; Smith L; Bartholomew R M; Boggiano C A; Gold D P; Sobol R E  
 CS Sidney Kimmel Cancer Center, Clemma A. Hewitt Gene Therapy Laboratory, San Diego, California, USA.  
 NC AC035 (NIA)  
 CA42909 (NCI)  
 CA67814 (NCI)  
 SO JOURNAL OF IMMUNOTHERAPY, (1997 Nov) 20 (6) 437-48.  
 Journal code: 9706083. ISSN: 1524-9557.  
 CY United States  
 DT Journal: Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 199801  
 ED Entered STN: 19980130  
 Last updated on STN: 19980130  
 Entered Medline: 19980120

L6 ANSWER 3 OF 12 CANCERLIT  
 AN 1998073914  
 DN 98073914  
 TI Construction and characterization of retroviral vectors for interleukin-2 gene therapy.  
 AU Fakhrai H; Shawler D L; Van Beveren C; Lin H; Dorigo O; Solomon M J; Gjerstet R A; Smith L; Bartholomew R M; Boggiano C A; Gold D P; Sobol R E  
 CS Sidney Kimmel Cancer Center, Clemma A. Hewitt Gene Therapy Laboratory, San Diego, California, USA.  
 NC AC035 (NIA)  
 CA67814 (NCI)  
 CA42909 (NCI)  
 SO JOURNAL OF IMMUNOTHERAPY, (1997) . Vol. 20, No. 6, pp. 437-48.  
 Journal code: CUO.  
 DT Journal: Article; (JOURNAL ARTICLE)  
 FS MEDL: L; Priority Journals  
 LA English  
 OS MEDLINE 98073914  
 EM 199802

L6 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2002 ACS  
 AN 2000:84650  
 DN 132:136415  
 TI Allogeneic cellular immunogens useful as cancer vaccines  
 IN Halpern, Michael S.; England, James M.  
 PA Allegheny University of the Health Sciences, USA  
 SO PCT Int. Appl., 77 pp.  
 CODEN: PIXD2

DT Patent  
 LA English  
 FAN CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 200004927	A1	20000203	WO 1999-US15594	19990708
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RM:	CH, CM, KE, LS, MW, SD, SL, SZ, UC, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BU, CF, CG, CI, CM, GN, GU, HN, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 9948819	A1	20000214	AU 1999-49819	19990708
EP 1100544	A1	20010523	EP 1999-933855	19990708
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
PRAI US 1998-93965P	P	19980724		
WO 1999-US15594	W	19990708		
RE. CNT 1				
THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD				
ALL CITATIONS AVAILABLE IN THE RE FORMAT				
PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9725860	A1	19970724	WO 1997-US582	19970113
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GR, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RM:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BU, CF, CG, CI, CM, GN, GU, HN, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
CA 2241952	AA	19970724	CA 1997-2241952	19970113
AU 9716992	A1	19970811	AU 1997-16992	19970113
AU 717356	B2	20000323	EP 1997-902934	19970113
EP 923284	A1	19990623		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
JP 2001501909	T2	20010213	JP 1997-526124	19970113
US 6365151	B1	20020402		
US 1996-10262P	P	19960119		
WO 1997-US582	W	19970113	US 1996-167322	19981007
US 1998-101226	B2	19980702		



Lomborg, Nils, Woodside, CA, UNITED STATES  
 PI US 2002086014 A1 20020704  
 AI US 2001-948939 A1 20010907 (9)  
 RLI Continuation-in-part of Ser. No. US 2000-644668, filed on 24 Aug 2000,  
 PRAI US 1999-150452P 19990824 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 4981  
 INCLM: 424/144.100  
 INCLS: 424/146.100; 530/388.260  
 NCLM: 424/144.100  
 NCLS: 424/146.100; 530/388.260  
 IC ICM: A61K039-395  
 ICS: C07K016-40  
 L6 ANSWER 7 OF 12 USPATFULT  
 AN 2002:69599 USPATFULT  
 TI Cellular immunogens comprising cognate proto-oncogenes  
 IN Halpern, Michael S, West Newton, MA, United States  
 PA Philadelphia Health and Educational Corporation, Philadelphia, PA,  
 PI United States (U.S. corporation)  
 AI US 1998-167322 B1 20020402  
 RLI Continuation-in-part of Ser. No. US 1998-101226, filed on 2 Jul 1998,  
 now abandoned Continuation-in-part of Ser. No. WO 1997-US582, filed on  
 13 Jan 1997  
 PRAI US 1996-10262P 19960119 (60)  
 DT Utility  
 FS GRANTED  
 LN.CNT 1838  
 INCLM: 424/093.210  
 INCLS: 424/093.200; 435/325.000; 435/320.100; 514/044.000  
 NCLM: 424/093.210  
 NCLS: 424/093.200; 435/320.100; 435/325.000; 514/044.000  
 IC ICM: A61K035-00  
 ICS: A61K048-00; C12N015-85; C12N015-63  
 EXF 435/325; 435/320.1; 424/93.2; 424/93.21; 514/44  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L6 ANSWER 8 OF 12 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
 AN 2002:220523 BIOSIS  
 DN PREV200200220523  
 TI A new generation of HSV BAC vectors for preparation of leukemia vaccines.  
 AU Thomassen, A. (1); Zibert, A. (1); Quang, H. (1); Glushkova, L. (1);  
 Dilloo, D. (1)  
 CS (1) Klinik f. Paediatrische Haematologie und Onkologie,  
 Universitaetsklinikum Dueseldorf, Dueseldorf Germany  
 SO Blood, (November 16, 2001) Vol. 98, No. 11 Part 1, pp. 695a.  
 Meeting Info.: 43rd Annual Meeting of the American Society of Hematology,  
 Part 1 Orlando, Florida, USA December 07-11, 2001  
 ISSN: 0006-4971.  
 DT Conference  
 LA English  
 L6 ANSWER 9 OF 12 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
 AN 2001:419136 BIOSIS  
 DN PREV200100419136  
 TI Comparative analysis of IFN-gamma B7.1 and antisense TGF-beta gene  
 transfer on the tumorigenicity of a poorly immunogenic metastatic mammary

carcinoma.  
 AU Wu, Rita S.; Kohle, James J.; Besselsen, David G.; Fong, Tim C.; Mack,  
 Vivian D.; McBarbren, Julie A.; Akporiaye, Emmanuel T. (1)  
 CS (1) Department of Microbiology and Immunology, University of Arizona, 1501  
 N. Campbell, Tucson, AZ, 85724; akporiaye@u.arizona.edu USA  
 SO Cancer Immunology Immunotherapy, (July, 2001) Vol. 50, No. 5, pp. 229-240.  
 print.  
 ISSN: 0340-7004.  
 DT Article  
 LA English  
 SL English  
 L6 ANSWER 10 OF 12 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
 AN 1998:48328 BIOSIS  
 DN PREV199800048328  
 TI Construction and characterization of retroviral vectors for interleukin-2  
 gene therapy.  
 AU Fakhrat, Habib; Shawler, Daniel L. (1); Van Beveren, Charles; Lin, Hong;  
 Dorigo, Oliver; Solomon, Michael J.; Gjerset, Ruth A.; Smith, Larry;  
 Bartholomew, Richard M.; Boggiano, Cesar A.; Gold, Daniel P.; Sobol,  
 Robert E.  
 CS (1) Sidney Kimmel Cancer Cent., 3099 Science Park Rd., San Diego, CA 92121  
 SO Journal of Immunotherapy, (Nov., 1997) Vol. 20, No. 6, pp. 437-448.  
 DT Article  
 LA English  
 L6 ANSWER 11 OF 12 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.  
 AN 2001255161 EMBASE  
 TI Comparative analysis of IFN-gamma, B7.1 and antisense TGF-beta, gene  
 transfer on the tumorigenicity of a poorly immunogenic metastatic mammary  
 carcinoma.  
 AU Wu R.S.; Kohle J.J.; Besselsen D.G.; Fong T.C.; Mack V.D.; McBarbren  
 J.A.; Akporiaye E.T.  
 CS E.T. Akporiaye, University of Arizona, Department of Microbiology, 1501 N.  
 Campbell, Tucson, AZ 85724, United States; akporiaye@u.arizona.edu  
 SO Cancer Immunology, Immunotherapy, (2001) 50/5 (229-240).  
 Refs: 88  
 ISSN: 0340-7004 CODEN: CIIMDN  
 CY Germany  
 DT Journal: Article  
 FS 016 Cancer  
 022 Human Genetics  
 026 Immunology, Serology and Transplantation  
 037 Drug Literature Index  
 LA English  
 SL English  
 L6 ANSWER 12 OF 12 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.  
 AN 97380111 EMBASE  
 DN 1997380111  
 TI Construction and characterization of retroviral vectors for interleukin-2  
 gene therapy.  
 AU Fakhrat H.; Shawler D.L.; Van Beveren C.; Lin H.; Dorigo O.; Solomon M.J.;  
 Gjerset R.A.; Smith L.; Bartholomew R.M.; Boggiano C.A.; Gold D.P.; Sobol  
 R.E.  
 CS Dr. D.L. Shawler, Sidney Kimmel Cancer Center, 3099 Science Park Rd, San  
 Diego, CA 92121, United States  
 SO Journal of Immunotherapy, (1997) 20/6 (437-448).  
 Refs: 34  
 ISSN: 1053-8550 CODEN: JOIME7  
 CY United States  
 DT Journal: Article  
 FS 004 Microbiology

016 Cancer  
026 Immunology, Serology and Transplantation  
LA English  
SL English

=> d his

(FILE 'HOME' ENTERED AT 09:10:35 ON 11 JUL 2002)

FILE 'MEDLINE, CANCERLIT, CAPLUS, USPATFULL, BIOSIS, EMBASE, CONFSCI'  
ENTERED AT 09:11:14 ON 11 JUL 2002

L1 538 S IMMUNOGEN? (S) TRANSGENE?  
L2 52 S L1 AND ALLOGEN?  
L3 27 S L2 AND PROMOT?  
L4 11 S L3 NOT PY>1998  
L5 1 S L2 AND CELL? (A) THERAP?  
L6 12 S L1 AND CELL? (A) VACCINE

=> s l1 and fibroblast  
L7 58 L1 AND FIBROBLAST

=> s l7 and administrat  
MISSING TERM AFTER ADMINISTRATION

Operators must be followed by a search term, L-number, or query name.

=>

=>

=>

=>

=>

YOU HAVE RECEIVED 8 CONSECUTIVE ARROW PROMPTS (=)  
The arrow (=) is the system prompt, where you enter a command. For an explanation of system commands, files, formats, etc., enter "HELP" and the name of the item you want explained at an arrow prompt (=). Enter "HELP COMMANDS" for a list of commands that can be used in this file. Enter "HELP MESSAGES" for a list of online explanations that are available. The "?" can be used as a synonym for "HELP".

Help is also available at any prompt, and after any error message. Enter "HELP" or "?" at a prompt to see an explanation of the options. After an error message, enter "HELP" or "?" at the next prompt and you will receive a more detailed explanation of the error and how to correct it.

Automatic help is also available. When AUHELP is 'ON', you will automatically receive help following an error message. For more information on AUHELP, enter "HELP SET AUHELP" at an arrow prompt (=).

Users who need additional assistance can contact the Help Desk at their nearest STN Service Center. Enter "HELP STN" for information on STN Service Centers. You may also choose to contact the database representative for the file you are searching, for more detailed help

on database content and search strategy. For information on how to contact database representatives for the current file, enter "HELP DESK" at an arrow prompt (=).  
IF YOU REQUIRE FURTHER HELP, PLEASE CONTACT YOUR LOCAL HELP DESK

=>

=>

=>

=>

=> this  
THIS IS NOT A RECOGNIZED COMMAND  
The previous command name entered was not recognized by the system. For a list of commands available to you in the current file, enter "HELP COMMANDS" at an arrow prompt (=).

=> d his

(FILE 'HOME' ENTERED AT 09:10:35 ON 11 JUL 2002)

FILE 'MEDLINE, CANCERLIT, CAPLUS, USPATFULL, BIOSIS, EMBASE, CONFSCI'  
ENTERED AT 09:11:14 ON 11 JUL 2002

L1 538 S IMMUNOGEN? (S) TRANSGENE?  
L2 52 S L1 AND ALLOGEN?  
L3 27 S L2 AND PROMOT?  
L4 11 S L3 NOT PY>1998  
L5 1 S L2 AND CELL? (A) THERAP?  
L6 12 S L1 AND CELL? (A) VACCINE  
L7 58 S L1 AND FIBROBLAST

=> s l7 and administrat  
L8 42 L7 AND ADMINISTRATION

=> dup rem l8  
PROCESSING COMPLETED FOR L8  
L9 42 DUP REM L8 (0 DUPLICATES REMOVED)

=> d 19 1-42

L9 ANSWER 1 OF 42 USPATFULL  
AN 2002:164809 USPATFULL  
TI Inducible eukaryotic expression system that regulates protein translation  
IN Leiden, Jeffrey M., Glencoe, IL, UNITED STATES  
PI US 2002086427 AL 20020704  
AI US 2001-815980 AI 20010322 (9)  
PRAI US 2000-191568P 20000323 (60)  
DT Utility  
FS APPLICATION  
LN CNT 2068  
INCL INCLM: 435/455.000  
NCL NCLM: 435/455.000  
IC [7]  
ICM: A61K031-70  
ICS: C12N015-63

L9 ANSWER 2 OF 42 USPATFULL  
AN 2002:157109 USPATFULL  
TI Novel chimeric promoters  
TI Punnonen, Juhana, Belmont, CA, UNITED STATES  
IN Wright, Anne, Woodside, CA, UNITED STATES

PI Semyonov, Andrey, San Francisco, CA, UNITED STATES  
 US 2002081708 A1 20020627  
 AI US 2001-886942 A1 20010621 (9)  
 PRAI US 2000-213829P 20000623 (60)  
 DT Utility  
 FS APPLICATION  
 LN CNT 3342  
 INCL INCLM: 435/235.100  
 NCL INCLS: 435/005.000; 536/023.720  
 NCLM: 435/235.100  
 NCLS: 435/005.000; 536/023.720  
 IC [7]  
 ICM: C120001-70  
 ICS: C07H021-04; C12N007-01

L9 ANSWER 3 OF 42 USPATFULL  
 AN 2002:157004 USPATFULL  
 TI Databases of regulatory sequences; methods of making and using same  
 IN Wolfe, Alan, Orinda, CA, UNITED STATES  
 Urnov, Eydor, Richmond, CA, UNITED STATES  
 Guschin, Dmitry, Richmond, CA, UNITED STATES  
 Collingwood, Trevor, San Pablo, CA, UNITED STATES  
 Li, Xiao-Yong, Richmond, CA, UNITED STATES  
 Johnstone, Brian, Benicia, CA, UNITED STATES  
 PI US 2002081603 A1 20020627  
 AI US 2001-844501 A1 20010427 (9)  
 PRAI US 2000-200590P 20000428 (60)  
 US 2000-214674P 20000627 (60)  
 US 2000-228566P 20000828 (60)  
 DT Utility  
 FS APPLICATION  
 LN CNT 5742  
 INCL INCLM: 435/006.000  
 NCL INCLS: 435/091.200  
 NCLM: 435/006.000  
 NCLS: 435/091.200  
 IC [7]  
 ICM: C120001-68  
 ICS: C12P019-34

L9 ANSWER 4 OF 42 USPATFULL  
 AN 2002:148654 USPATFULL  
 TI Purified and isolated pivi family genes and gene products and methods  
 IN Lin, Hailan, Durham, NC, UNITED STATES  
 PI US 2002076797 A1 20020620  
 AI US 2001-873737 A1 20010604 (9)  
 RLI Continuation-in-part of Ser. No. WO 1999-US28764, filed on 3 Dec 1999,  
 UNKNOWN  
 PRAI US 1998-110901P 19981204 (60)  
 DT Utility  
 FS APPLICATION  
 LN CNT 7192  
 INCL INCLM: 435/226.000  
 NCL INCLS: 435/325.000; 435/006.000; 435/069.100; 435/320.100; 536/023.200  
 NCLM: 435/226.000  
 NCLS: 435/325.000; 435/006.000; 435/069.100; 435/320.100; 536/023.200  
 IC [7]  
 ICM: C12N009-64  
 ICS: C120001-68; C07H021-04; C12P021-02; C12N005-06

L9 ANSWER 5 OF 42 USPATFULL  
 AN 2002:148570 USPATFULL  
 TI Methods for designing exogenous regulatory molecules

IN Wolfe, Alan, Orinda, CA, UNITED STATES  
 Urnov, Eydor, Richmond, CA, UNITED STATES  
 Guschin, Dmitry, Richmond, CA, UNITED STATES  
 Collingwood, Trevor, San Pablo, CA, UNITED STATES  
 Li, Xiao-Yong, Richmond, CA, UNITED STATES  
 Johnstone, Brian, Benicia, CA, UNITED STATES  
 PI US 2002076711 A1 20020620  
 AI US 2001-844493 A1 20010427 (9)  
 PRAI US 2000-200590P 20000428 (60)  
 DT Utility  
 FS APPLICATION  
 LN CNT 5246  
 INCL INCLM: 435/006.000  
 NCL INCLS: 435/091.200; 702/020.000  
 NCLM: 435/006.000  
 NCLS: 435/091.200; 702/020.000  
 IC [7]  
 ICM: C120001-68  
 ICS: G06F019-00; G01N033-48; G01N033-50; C12P019-34

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 6 OF 42 USPATFULL  
 AN 2002:133856 USPATFULL  
 TI Tolerance and chronic hepatitis C virus  
 IN Rallard, Xavier, San Francisco, CA, UNITED STATES  
 PI US 2002068714 A1 20020606  
 AI US 2001-894845 A1 20010627 (9)  
 PRAI US 2000-214583P 20000627 (60)  
 DT Utility  
 FS APPLICATION  
 LN CNT 1002  
 INCL INCLM: 514/044.000  
 NCL INCLS: 424/093.210; 800/014.000  
 NCLM: 514/044.000  
 NCLS: 424/093.210; 800/014.000  
 IC [7]  
 ICM: A01K067-027  
 ICS: A61K048-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 7 OF 42 USPATFULL  
 AN 2002:99410 USPATFULL  
 TI Methods and compositions for the treatment and/or diagnosis of  
 IN Solomon, Beki, Herzlia Pituach, ISRAEL  
 PI US 2002052311 A1 20020502  
 AI US 2001-808037 A1 20010315 (9)  
 RLI Continuation-in-part of Ser. No. US 2000-629971, filed on 31 Jul 2000,  
 PENDING Continuation-in-part of Ser. No. US 1999-473653, filed on 29 Dec  
 1999, PENDING  
 PRAI US 1999-152417P 19990903 (60)  
 DT Utility  
 FS APPLICATION  
 LN CNT 4074  
 INCL INCLM: 514/002.000  
 NCL INCLS: 424/093.210  
 NCLM: 514/002.000  
 NCLS: 424/093.210  
 IC [7]  
 ICM: A61K048-00  
 ICS: A61K038-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 8 OF 42 USPATFULT.  
 AN 2002:54662 USPATFULT.  
 TI Use of trans-activation and cis-activation to modulate the persistence  
 IN of expression of a transgene  
 PA Brough, Douglas E., Galthersburg, MD, UNITED STATES  
 PI Kovecki, Imre, Rockville, MD, UNITED STATES  
 AI US 200201823 AI 20020314  
 RLI US 2001-873486 AI 20010604 (9)  
 Continuation of Ser. No. WO 1999-US28637, filed on 3 Dec 1999, UNKNOWN  
 Continuation-in-part of Ser. No. US 1998-205014, filed on 4 Dec 1998,  
 GRANTED, Pat. No. US 6225113  
 DT Utility  
 FS APPLICATION  
 LN.CNT 1159  
 INCL INCLM: 435/320.100  
 NCL INCLS: 514/044.000  
 NCLM: 435/320.100  
 NCLS: 514/044.000  
 IC (7)  
 ICM: A61K048-00  
 ICS: C12N015-86  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 9 OF 42 USPATFULT.  
 AN 2002:48003 USPATFULT.  
 TI Transgene expression systems  
 IN Kaplan, Johanne, Sherborn, MA, UNITED STATES  
 PI Armentano, Donna, Belmont, MA, UNITED STATES  
 AI Gregory, Richard J., Westford, MA, UNITED STATES  
 RLI US 2002028194 AI 20020307  
 US 2001-924925 AI 20010808 (9)  
 Continuation of Ser. No. US 1999-416673, filed on 12 Oct 1999, PENDING  
 Continuation of Ser. No. WO 1998-US7839, filed on 14 Apr 1998, UNKNOWN  
 Continuation of Ser. No. US 1997-839679, filed on 14 Apr 1997, GRANTED,  
 Pat. No. US 6100086  
 DT Utility  
 FS APPLICATION  
 LN.CNT 1489  
 INCL INCLM: 424/093.210  
 NCL INCLS: 435/456.000; 435/320.100  
 NCLM: 424/093.210  
 NCLS: 435/456.000; 435/320.100  
 IC (7)  
 ICM: A61K048-00  
 ICS: C12N015-861  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 10 OF 42 USPATFULT.  
 AN 2002:37318 USPATFULT.  
 TI Therapeutic DNA vaccination  
 IN Lisiewicz, Juliana, Bethesda, MD, UNITED STATES  
 PI Lori, Franco, Bethesda, MD, UNITED STATES  
 AI US 2002022034 AI 20020221  
 RLI US 2001-863806 AI 20010523 (9)  
 PENDING  
 Continuation-in-part of Ser. No. US 1998-153198, filed on 15 Sep 1998,  
 GRANTED, Pat. No. US 6225113  
 DT Utility  
 FS APPLICATION  
 LN.CNT 2171  
 INCL INCLM: 424/208.100  
 NCL INCLS: 514/023.000; 514/044.000  
 NCLM: 424/208.100

IC NCLS: 514/023.000; 514/044.000  
 (7)  
 ICM: A61K039-21  
 ICS: A61K031-70; A61K048-00  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 11 OF 42 USPATFULT.  
 AN 2002:32230 USPATFULT.  
 TI Chimeric adenoviral vectors  
 IN Lusky, Monika, Freiburg, GERMANY, FEDERAL REPUBLIC OF  
 PI Winter, Arend Jan, Strasbourg, FRANCE  
 AI US 2002019051 AI 20020214  
 RLI US 2001-867475 AI 20010531 (9)  
 Continuation-in-part of Ser. No. US 2000-463486, filed on 27 Jan 2000,  
 PENDING  
 FR 1998-6654 19980527  
 WO 1999-FR1238 19990527  
 DT Utility  
 FS APPLICATION  
 LN.CNT 2525  
 INCL INCLM: 435/457.000  
 NCL INCLS: 435/235.100  
 NCLM: 435/457.000  
 NCLS: 435/235.100  
 IC (7)  
 ICM: C12N015-861  
 ICS: C12N007-01  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 12 OF 42 USPATFULT.  
 AN 2002:31965 USPATFULT.  
 TI Methods for producing polynucleotide libraries in vaccinia virus  
 IN Zanderer, Maurice, Pittsford, NY, UNITED STATES  
 PI University of Rochester (U.S. corporation)  
 AI US 2002018785 AI 20020214  
 RLI US 2001-822250 AI 20010402 (9)  
 Division of Ser. No. US 1997-935377, filed on 22 Sep 1997, PENDING  
 DT Utility  
 FS APPLICATION  
 LN.CNT 3321  
 INCL INCLM: 424/232.100  
 NCL INCLS: 435/235.100; 435/456.000  
 NCLM: 424/232.100  
 NCLS: 435/235.100; 435/456.000  
 IC (7)  
 ICM: A61K039-285  
 ICS: C12N015-863; C12N007-01  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 13 OF 42 USPATFULT.  
 AN 2002:27111 USPATFULT.  
 TI Diagnostics and therapeutics for macular degeneration-related disorders  
 IN Hageman, Gregory S., Coralville, IA, UNITED STATES  
 PI Mullins, Robert F., Coralville, IA, UNITED STATES  
 AI US 2002015957 AI 20020207  
 RLI US 2001-845745 AI 20010430 (9)  
 PENDING  
 FR 1998-6654 19980527  
 WO 2000-200698P 20000429 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 3111  
 INCL INCLM: 435/006.000  
 NCL INCLS: 351/200.000  
 NCLM: 435/006.000  
 NCLS: 351/200.000

IC [7]  
 ICM: C120001-68  
 ICS: A61003-00  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 14 OF 42 USPTAFULL  
 AN 2002:69599 USPTAFULL  
 TI Cellular immunogens comprising cognate proto-oncogenes  
 IN Halpern, Michael S., West Newton, MA, United States  
 PA Philadelphia Health and Educational Corporation, Philadelphia, PA,  
 PI United States (U.S. corporation)  
 AI US 6365151 B1 20020402  
 RLI US 1998-167322 19981007 (9)  
 Continuation-in-part of Ser. No. US 1998-101226, filed on 2 Jul 1998,  
 now Abandoned Continuation-in-part of Ser. No. WO 1997-US582, filed on  
 13 Jan 1997  
 PRAI US 1996-10262P 19960119 (60)  
 DT Utility  
 FS GRANTED  
 LN.CNT 1838  
 INCL INCLM: 424/093.210  
 INCLM: 424/093.200; 435/325.000; 435/320.100; 514/044.000  
 NCL NCLM: 424/093.210  
 NCLM: 424/093.200; 435/320.100; 435/325.000; 514/044.000  
 IC [7]  
 ICM: A61K035-00  
 ICS: A61K048-00; C12N015-85; C12N015-63  
 435/325; 435/320.1; 424/93.2; 424/93.21; 514/44  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 15 OF 42 USPTAFULL  
 AN 2002:57389 USPTAFULL  
 TI Transgene expression systems  
 IN Kaplan, Johanne, Sherborn, MA, United States  
 PA Argemano, Donna, Belmont, MA, United States  
 PI Gregory, Richard J., Westford, MA, United States  
 US 6358507 B1 20020319  
 US 1998-416673 19991012 (9)  
 Continuation of Ser. No. WO 1998-US7839, filed on 14 Apr 1998  
 Continuation of Ser. No. US 1997-839679, filed on 14 Apr 1997, now  
 patented, Pat. No. US 6100086  
 DT Utility  
 FS GRANTED  
 LN.CNT 1500  
 INCL INCLM: 424/093.200  
 INCLM: 424/093.600; 435/320.100; 435/069.100; 435/455.000; 435/456.000;  
 435/325.000; 435/366.000; 435/091.100; 435/091.400; 435/091.410;  
 435/091.420; 435/371.000  
 NCL NCLM: 424/093.200  
 NCLM: 424/093.600; 435/069.100; 435/091.100; 435/091.400; 435/091.410;  
 435/091.420; 435/320.100; 435/325.000; 435/366.000; 435/371.000;  
 435/455.000; 435/456.000  
 IC [7]  
 ICM: A61K048-00  
 ICS: C12N015-63; C12N015-861; C12N015-34  
 435/320.1; 435/69.1; 435/455; 435/456; 435/325; 435/366; 435/91.1;  
 435/91.4; 435/91.41; 435/91.42; 435/371; 424/93.2; 424/93.6  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 16 OF 42 USPTAFULL  
 AN 2002:34423 USPTAFULL  
 TI Noninvasive genetic immunization, expression products therefrom and uses

IN thereof  
 Tang, De-chu C., Birmingham, AL, United States  
 Marks, Donald H., Rockaway, NJ, United States  
 Curriel, David T., Birmingham, AL, United States  
 Shi, Zhongkai, Birmingham, AL, United States  
 van Kampen, Kent Rigby, Hoover, AL, United States  
 The UAB Research Foundation, Birmingham, AL, United States (U.S.  
 corporation)  
 PI US 6348450 B1 20020219  
 US 2000-563826 20000503 (9)  
 AI US 1998-75113P 19980211 (60)  
 RLI Continuation-in-part of Ser. No. US 2000-533149, filed on 23 Mar 2000  
 No. WO 1998-US16739, filed on 13 Aug 1998  
 PRAI US 1999-122216P 19990503 (60)  
 US 1998-75113P 19980211 (60)  
 US 1997-55520P 19970813 (60)  
 DT Utility  
 FS GRANTED  
 LN.CNT 2393  
 INCL INCLM: 514/044.000  
 INCLM: 424/093.210; 435/320.100; 435/375.000  
 NCL NCLM: 514/044.000  
 NCLM: 424/093.210; 435/320.100; 435/375.000  
 IC [7]  
 ICM: A61K048-00  
 ICS: C12N015-63  
 514/44; 424/93.21; 435/320.1; 435/375  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 17 OF 42 USPTAFULL  
 AN 2002:9856 USPTAFULL  
 TI Gene construct encoding a heterologous produgx-activating enzyme and a  
 cell targeting moiety  
 IN Emery, Stephen Charles, Macleesfield, UNITED KINGDOM  
 PA Blakey, David Charles, Macleesfield, UNITED KINGDOM  
 PI Zeneca Limited, London, UNITED KINGDOM (non-U.S. corporation)  
 US 6339070 B1 20020115  
 WO 9851787 19981119  
 WO 1999-423439 19991109 (9)  
 WO 1998-CB1294 19980505  
 PRAI GB 1997-9421 19970510 PCT 371 date  
 DT Utility  
 FS GRANTED  
 LN.CNT 3084  
 INCL INCLM: 514/044.000  
 INCLM: 424/093.200; 435/320.100; 435/325.000; 435/455.000; 435/458.000  
 NCL NCLM: 514/044.000  
 NCLM: 424/093.200; 435/320.100; 435/325.000; 435/455.000; 435/458.000  
 IC [7]  
 ICM: A61P048-00  
 ICS: C12N015-00; C12N015-63; C12N015-88  
 514/44; 536/23.1; 536/24.1; 435/320.1; 435/328; 435/456; 435/69.7;  
 424/93.21; 424/134.1; 424/178.1; 424/94.1; 424/277.1  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 18 OF 42 USPTAFULL  
 AN 2001:229422 USPTAFULL  
 TI HIGH EFFICIENCY GENETIC MODIFICATION METHODS  
 IN MCCLAUGHLIN-TAYLOR, ELIZABETH, SAN CLEMENTE, CA, United States  
 KRUGER, MARK, ENCINITAS, CA, United States  
 LUNDAK, CHERYL, SAN DIEGO, CA, United States  
 KILLION, CATHERINE, LONG BEACH, CA, United States  
 PI US 2001051374 A1 20011213

AI US 1999-454820 A1 19991203 (9)  
 RLI Continuation of Ser. No. US 1998-132541, filed on 11 Aug 1998, GRANTED.  
 PRAI Pat. No. US 6114113  
 DT US 1997-55453P 19970811 (60)  
 FS UTILITY  
 IN APPLICATION  
 LN CNT 3013  
 INCL INCLM: 435/455.000  
 NCL INCLS: 435/456.000; 435/320.100; 435/372.300  
 NCLM: 435/455.000  
 NCLS: 435/456.000; 435/320.100; 435/372.300  
 IC [7]  
 ICM: C12N001-68  
 ICS: C12N015-00; C12N015-09; C12N015-63; C12N015-70; C12N015-74;  
 C12N005-08; C12N015-85; C12N015-87; C12N015-86  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 19 OF 42 USPATFULT  
 AN 2001:235126 USPATFULT  
 TI Hydrogel compositions for controlled delivery of virus vectors and  
 methods of use thereof  
 IN Levy, Robert J.; Merion Station, PA, United States  
 Crombleholme, Timothy; Haverford, PA, United States  
 Vyavahare, Narendra; Erial, NJ, United States  
 PA The Children's Hospital of Philadelphia, Philadelphia, PA, United States  
 (U.S. corporation) B1 20011225  
 PI US 6331194  
 AI US 2000-487854 200000119 (9)  
 PRAI US 1999-116538P 19990119 (60)  
 DT UTILITY  
 FS GRANTED  
 LN CNT 3154  
 INCL INCLM: 435/450.000  
 NCL INCLS: 435/006.000; 424/001.250; 424/001.330; 424/001.530; 424/497.000;  
 NCLM: 435/003.000; 536/023.100  
 NCLS: 424/001.250; 424/001.330; 424/001.530; 424/497.000; 435/006.000;  
 IC [7]  
 ICM: C12N015-63  
 ICS: C120001-68; A61K051-00; C08B037-04; C07H021-02  
 514/44; 435/6; 435/69.1; 435/91.1; 435/455; 435/458; 536/23.1; 536/24.5;  
 536/3; 424/1.25; 424/1.33; 424/1.53; 424/497  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 20 OF 42 USPATFULT  
 AN 2001:226239 USPATFULT  
 TI Deleted adenovirus vectors and methods of making and administering the  
 same  
 IN Amalfitano, Andrea; Durham, NC, United States  
 Chen, Yuan Tsong; Chapel Hill, NC, United States  
 Hu, Hui-min; Memphis, TN, United States  
 PA Duke University, Durham, NC, United States (U.S. corporation)  
 US 6328958 B1 20011211  
 AI US 1999-384749 19990827 (9)  
 PRAI US 1999-145742P 19980828 (60)  
 DT UTILITY  
 FS GRANTED  
 LN CNT 3884  
 INCL INCLM: 424/093.200  
 NCL INCLS: 435/091.400; 435/320.100; 435/455.000; 514/044.000  
 NCLM: 424/093.200  
 NCLS: 435/091.400; 435/320.100; 435/455.000; 514/044.000  
 IC [7]

ICM: A61K048-00  
 ICS: C12N015-88  
 514/44; 435/320.1; 435/455; 435/69.1; 435/91.4; 536/23.4; 536/23.5;  
 424/93.2  
 EXF CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 21 OF 42 USPATFULT  
 AN 2001:167936 USPATFULT  
 TI Hepatitis therapeutics  
 IN Jolly, Douglas J.; Leucadia, CA, United States  
 Chang, Stephen M. W.; Poway, CA, United States  
 Lee, William T. L.; Carlsbad, CA, United States  
 Townsend, Kay; Encinitas, CA, United States  
 O'Dea, Joanne; La Jolla, CA, United States  
 PA Chiron Corporation, Emeryville, CA, United States (U.S. corporation)  
 PI US 6297048 B1 20011002  
 AI US 1995-483511 19950607 (8)  
 RLI Continuation-in-part of Ser. No. US 1995-374414, filed on 19 Jan 1995,  
 now abandoned Continuation-in-part of Ser. No. US 1994-286829, filed on  
 5 Aug 1994, now abandoned Continuation-in-part of Ser. No. US  
 1993-102132, filed on 4 Aug 1993, now abandoned Continuation-in-part of  
 Ser. No. US 1993-32385, filed on 17 Mar 1993, now abandoned  
 Continuation-in-part of Ser. No. US 1992-830417, filed on 4 Feb 1992,  
 now abandoned  
 DT UTILITY  
 FS GRANTED  
 LN CNT 3732  
 INCL INCLM: 435/320.100  
 NCL INCLS: 435/069.300  
 NCLM: 435/320.100  
 NCLS: 435/069.300  
 IC [7]  
 ICM: C12N015-63  
 ICS: C12P021-02  
 435/69.1; 435/69.3; 435/320.1; 424/228.1  
 EXF CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 22 OF 42 USPATFULT  
 AN 2001:152765 USPATFULT  
 TI Nucleic acid delivery vehicles  
 IN O'Riordan, Catherine R.; Boston, MA, United States  
 Madsworth, Samuel C.; Shrewsbury, MA, United States  
 PA Genzyme Corporation, Cambridge, MA, United States (U.S. corporation)  
 PI US 6287857 B1 20010911  
 AI US 1999-426860 19991025 (9)  
 RLI Continuation-in-part of Ser. No. WO 1999-US2680, filed on 8 Feb 1999  
 PRAI US 1998-107471P 19981106 (60)  
 DT US 1998-135092P 19981103 (60)  
 FS UTILITY  
 INCL INCLM: 435/320.100  
 NCL INCLS: 536/023.100; 536/024.200  
 NCLM: 435/320.100  
 NCLS: 536/023.100; 536/024.200  
 IC [7]  
 ICM: C12N015-63  
 ICS: C07H021-04  
 435/320.1; 530/350; 536/23.1; 536/24.2  
 EXF CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 23 OF 42 USPATFULT  
 AN 2001:116818 USPATFULT  
 TI Packaging systems for human recombinant adenovirus to be used in gene

therapy  
IN Fallaux, Frits J., Leiderdorp, Netherlands  
Hoebe, Robert C., Leiden, Netherlands  
Bout, Abraham, Moerkapelle, Netherlands  
Valerio, Domenico, Leiden, Netherlands  
van der Eb, Alex J., Oegstgeest, Netherlands  
Schouten, Govert, Leiden, Netherlands  
PA Introgene B.V., Leiden, Netherlands  
US 6265212 B1 20010724  
PI US 1999-356575 19990719 (9)  
AI US 1997-356575 19990719 (9)  
RLI Continuation-in-part of Ser. No. US 1997-793170, filed on 25 Mar 1997,  
now patented. Pat. No. US 5994128  
PRAI EP 1995-201611 19950615  
EP 1995-201728 19950626  
DT Utility  
FS GRANTED  
INCL INCLM: 435/320.100  
INCLM: 435/325.000; 435/069.100; 435/320.100; 435/235.100; 424/093.210;  
536/023.100  
NCLM: 435/320.100  
NCLM: 424/093.210; 435/069.100; 435/235.100; 435/325.000; 536/023.100  
IC [7]  
ICM: C12N015-63  
ICS: C12N015-00; C12N015-09; C12N015-11  
EXF 435/325; 435/69.1; 435/320.1; 435/455; 435/235.1; 424/93.21; 536/23.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L9 ANSWER 24 OF 42 USPTFULT  
AN 2001:82751 USPTFULT  
TI Induction of immune response to antigens expressed by recombinant  
adeno-associated virus  
IN Kurtzman, Gary J., Menlo Park, CA, United States  
Engelman, Edgar G., Atherton, CA, United States  
Podakoff, Greg M., Fullerton, CA, United States  
Brockstedt, Dirk G., Palo Alto, CA, United States  
PA Avigen, Inc., CA, United States (U.S. corporation)  
PI US 6244246 B1 20010605  
AI US 1998-121162 19980723 (9)  
PRAI US 1997-53733P 19970725 (60)  
DT Utility  
FS Granted  
INCL INCLM: 514/044.000  
INCLM: 435/320.100; 435/325.000  
NCLM: 514/044.000  
NCLM: 435/320.100; 435/325.000  
IC [7]  
ICM: A61K048-00  
ICS: C12N015-63; C12N015-85  
EXF 435/320.1; 435/325.514/44  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L9 ANSWER 25 OF 42 USPTFULT  
AN 2001:40206 USPTFULT  
TI Inhibition of smooth muscle cell migration by heme oxygenase I  
IN Nabel, Gary J., Washington, DC, United States  
Nabel, Elizabeth G., Washington, DC, United States  
PA The Regents of the University of Michigan, Ann Arbor, MI, United States  
(U.S. corporation)  
PI US 6203991 B1 20010320  
AI US 1999-378528 19990820 (9)  
PRAI US 1998-97707P 19980821 (60)  
DT Utility

FS Granted  
INCL INCLM: 435/006.000  
INCLM: 435/320.100; 435/458.000; 514/044.000; 536/023.100  
NCLM: 435/006.000  
NCLM: 435/320.100; 435/458.000; 514/044.000; 536/023.100  
IC [7]  
ICM: C12C001-68  
ICS: C12N015-63; C12N015-88; A61K048-00; C07H021-04  
EXF 435/6; 435/320.1; 435/458.514/44; 536/23.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L9 ANSWER 26 OF 42 USPTFULT  
AN 2000:14950 USPTFULT  
TI Circular DNA expression cassettes for in vivo gene transfer  
IN Crouzet, Joel, Sceaux, France  
Scherman, Daniel, Paris, France  
Cameron, Beatrice, Paris, France  
Wills, Pierre, Paris, France  
PA Darguet, Anne-Marie, Villet-sur-Seine, France  
Rhône-Poulenc Rorer S.A., Antony, France (non-U.S. corporation)  
PI US 6143530 20001107  
AI US 1997-894511 19970819 (8)  
WO 1996-FR274 19960221  
PCT 371 date  
19970819 PCT 102(e) date  
PRAI FR 1995-2117 19950223  
DT Utility  
FS Granted  
INCL INCLM: 435/091.420  
INCLM: 435/091.100; 435/091.400; 435/320.100; 435/325.000; 435/252.300;  
435/252.330; 435/254.110; 435/455.000; 514/044.000  
NCLM: 435/091.420  
NCLM: 435/091.100; 435/091.400; 435/252.300; 435/252.330; 435/254.110;  
435/320.100; 435/325.000; 435/455.000; 514/044.000  
IC [7]  
ICM: C12N015-64  
ICS: C12N015-79; C12N015-70; C12N001-21; C12N005-10  
EXF 514/44; 435/320.1; 435/325.435/252.3; 435/252.33; 435/254.11; 435/91.1;  
435/91.4; 435/91.42; 435/455  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L9 ANSWER 27 OF 42 USPTFULT  
AN 2000:146160 USPTFULT  
TI Defective viral vaccine particles obtained in vivo or ex vivo  
IN Klatzmann, David, Paris, France  
Salzman, Jean-Loup, Paris, France  
PA Université Pierre et Marie Curie (Paris VI), Paris, France (non-U.S.  
corporation)  
PI US 6140114 20001031  
AI US 1998-166147 19981005 (9)  
DT Utility  
FS Granted  
INCL INCLM: 435/320.100  
INCLM: 424/184.100; 424/187.100; 424/188.100; 424/204.100;  
435/147.000FOR; 435/157.000FOR; 435/180.000FOR; 435/182.000FOR;  
435/190.000FOR; 536/023.100; 536/023.720  
NCLM: 435/320.100  
NCLM: 424/184.100; 424/187.100; 424/188.100; 424/204.100; 536/023.100;  
536/023.720  
IC [7]

ICM: C12N015-00  
 435/320.1; 435/FOR147; 435/FOR148; 435/FOR157; 435/FOR180; 435/FOR182;  
 435/FOR190; 424/184.1; 424/185.1; 424/186.1; 424/187.1; 424/188.1;  
 424/189.1; 424/192.1; 424/196.1; 424/199.1; 424/204.1; 424/228.1;  
 935/22; 935/23; 935/32; 935/55; 935/57; 935/65; 536/23.1; 536/23.72  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 28 OF 42 USPTAFULL  
 AN 2000:142359 USPTAFULL  
 TI Prostate specific enhancer polynucleotides and methods of use thereof  
 IN Henderson, Daniel R., Palo Alto, CA, United States  
 PA Caldon, Inc., Sunnyvale, CA, United States (U.S. corporation)  
 PI US 6136732 20001024  
 AI US 1997-891581 19970711 (8)  
 RLI Continuation of Ser. No. US 1995-380916, filed on 30 Jan 1995, now  
 patented Pat. No. US 5648478 which is a continuation-in-part of Ser.  
 No. US 1994-182247, filed on 13 Jan 1994, now patented, Pat. No. US  
 5830686  
 DT Utility  
 FS Granted  
 LN.CNT 1773  
 INCL INCLM: 514/044.000  
 INCLS: 536/024.100; 435/320.100; 435/325.000; 435/455.000  
 NCLM: 514/044.000  
 NCLS: 435/320.100; 435/325.000; 435/455.000; 536/024.100  
 IC [7]  
 ICM: A61K048-00  
 ICS: C07H021-04; C12N005-00; C12N015-00  
 800/2; 514/44; 424/93.21; 435/325; 435/320.1; 435/172.3  
 EXP INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 29 OF 42 USPTAFULL  
 AN 2000:138079 USPTAFULL  
 TI Methods and compositions for enhanced stability of non-adenoviral DNA  
 IN Kay, Mark A., Seattle, WA, United States  
 PA Lieber, Andre, Seattle, WA, United States  
 PI US 6132969 20001017  
 AI US 1997-872657 19971118 (8)  
 RLI Continuation-in-part of Ser. No. US 1997-867012, filed on 2 Jun 1997,  
 now abandoned  
 PRAI US 1996-18928P 19960603 (60)  
 DT Utility  
 FS Granted  
 LN.CNT 1601  
 INCL INCLM: 435/069.100  
 INCLS: 435/448.000; 435/455.000; 435/456.000; 435/320.100  
 NCLM: 435/069.100  
 NCLS: 435/320.100; 435/448.000; 435/455.000; 435/456.000  
 IC [7]  
 ICM: C12N015-00  
 ICS: 435/172.3; 435/69.1; 435/320.1; 435/370; 435/458; 435/235.1; 514/44;  
 536/23.1; 536/23.72; 536/29.1  
 EXP INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 30 OF 42 USPTAFULL  
 AN 2000:117494 USPTAFULL  
 TI High efficiency genetic modification method  
 IN McLaughlin-Taylor, Elizabeth, San Clemente, CA, United States  
 PA Krueger, Mark, Encinitas, CA, United States  
 PI Lundak, Cheryl, San Diego, CA, United States  
 AI Killion, Catherine, Long Beach, CA, United States  
 PA Chiron Corporation, Emeryville, CA, United States (U.S. corporation)  
 PI US 6114113 20000905

AI US 1998-132541 19980811 (9)  
 PRAI US 1997-55453P 19970811 (60)  
 DT Utility  
 FS Granted  
 LN.CNT 3069  
 INCL INCLM: 435/005.000  
 INCLS: 435/440.000; 435/455.000; 435/456.000; 435/372.300  
 NCLM: 435/005.000  
 NCLS: 435/372.300; 435/440.000; 435/455.000; 435/456.000  
 IC [7]  
 ICM: C12N001-68  
 ICS: C12Q001-70; C12N015-86  
 514/44; 435/320.1; 435/235.1; 435/325; 435/375; 435/440; 435/455;  
 424/93.1; 424/93.2  
 EXP INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 31 OF 42 USPTAFULL  
 AN 2000:113772 USPTAFULL  
 TI Diminishing viral gene expression by promoter replacement  
 IN Fong, Bingliang, Houston, TX, United States  
 PA Roth, Jack A., Houston, TX, United States  
 PI Board of Regents, The University of Texas System, Austin, TX, United  
 States (U.S. corporation)  
 AI US 6110744 20000829  
 RLI US 1997-968014 19971112 (8)  
 PRAI US 1996-30675P 19961113 (60)  
 DT Utility  
 FS Granted  
 LN.CNT 3104  
 INCL INCLM: 435/456.000  
 INCLS: 435/320.100; 536/023.100; 536/023.500; 536/023.700; 536/023.720;  
 536/024.100  
 NCLM: 435/456.000  
 NCLS: 435/320.100; 536/023.100; 536/023.500; 536/023.700; 536/023.720;  
 536/024.100  
 IC [7]  
 ICM: C12N015-64  
 ICS: C12N015-34; C12N015-12  
 435/69.1; 435/325; 435/320.1  
 EXP INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 32 OF 42 USPTAFULL  
 AN 2000:113519 USPTAFULL  
 TI Liposomal delivery system for biologically active agents  
 IN Thierry, Alain R., Strasbourg, France  
 PA The United States of America as represented by the Department of Health  
 and Human Services, Washington, DC, United States (U.S. government)  
 PI US 6110490 20000829  
 AI US 1996-522246 19950804  
 WO 1995-US9867 19950129  
 RLI Continuation-in-part of Ser. No. US 1994-286730, filed on 5 Aug 1994  
 DT Utility  
 FS Granted  
 LN.CNT 1758  
 INCL INCLM: 424/450.000  
 INCLS: 424/400.000; 935/054.000  
 NCLM: 424/450.000  
 NCLS: 424/400.000  
 IC [7]  
 ICM: A61K009-127  
 ICS: 424/450; 935/54  
 EXP INDEXING IS AVAILABLE FOR THIS PATENT.



L9 ANSWER 33 OF 42 USPATFULTL  
 AN 2000:109332 USPATFULTL  
 TI Entomopoxvirus-vertebrate gene delivery vector and method  
 IN Moyer, Richard W., Gainesville, FL, United States  
 PI Li Yi, Gainesville, FL, United States  
 PI Hall, Richard L., Gainesville, FL, United States  
 PI University of Florida, Gainesville, FL, United States (U.S. corporation)  
 AI US 6106825  
 AI US 1997-852629  
 AI US 1997-852629 19970507 (8)  
 DT Utility  
 FS Granted  
 INCL INCLM: 424/093.200  
 INCLM: 424/093.100; 435/235.100; 435/325.000; 435/456.000; 435/457.000;  
 NCLM: 424/093.200  
 NCLM: 424/093.100; 435/235.100; 435/325.000; 435/456.000; 435/457.000;  
 NCLM: 424/093.100; 435/235.100; 435/325.000; 435/456.000; 435/457.000;  
 IC [7]  
 ICM: A01N063-00  
 ICS: C12N007-01; C12N005-10; C12N015-63  
 EXF 435/235.1; 435/325; 435/320.1; 435/172.3; 435/456; 435/457; 514/44;  
 424/93.1; 424/93.21; 424/93.2  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L9 ANSWER 34 OF 42 USPATFULTL  
 AN 2000:102119 USPATFULTL  
 TI Transgene expression systems  
 IN Kaplan, Johanne, Sherborn, MA, United States  
 PI Armentano, Donna, Belmont, MA, United States  
 PI Gregory, Richard J., Westford, MA, United States  
 PI Genzyme Corporation, Cambridge, MA, United States (U.S. corporation)  
 AI US 6100086  
 AI US 1997-839679 19970414 (8)  
 DT Utility  
 FS Granted  
 INCL INCLM: 435/320.100  
 INCLM: 435/457.000; 435/458.000; 536/023.720; 552/544.000  
 NCLM: 435/320.100  
 NCLM: 435/457.000; 435/458.000; 536/023.720; 552/544.000  
 IC [7]  
 ICM: C12N015-86  
 ICS: C07D009-00  
 EXF 435/320.1; 435/69.1; 435/455; 435/456; 435/457; 435/458; 424/450;  
 424/93.2; 424/93.6; 536/23.72; 536/23.1; 536/24.1; 552/544; 514/44  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L9 ANSWER 35 OF 42 USPATFULTL  
 AN 2000:80736 USPATFULTL  
 TI Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides  
 IN and their use in gene therapy  
 IN Mixson, A. James, 1 Baderwood Ct., Rockville, MD, United States 20855  
 PI US 6080728 20000627  
 PI US 1997-985526 19971205 (8)  
 RLI Continuation-in-part of Ser. No. US 1996-680845, filed on 16 Jul 1996,  
 EP 1997-112154 19970716  
 DT Utility  
 FS Granted  
 INCL INCLM: 514/044.000  
 INCLM: 424/450.000

NCL INCLM: 514/044.000  
 NCLM: 424/450.000  
 IC [7]  
 ICM: A61K048-00  
 EXF 514/44; 424/450  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L9 ANSWER 36 OF 42 USPATFULTL  
 AN 2000:54082 USPATFULTL  
 TI Tissue-specific enhancer active in prostate  
 IN Henderson, Daniel R., Palo Alto, CA, United States  
 PI Calydon, Inc., Sunnyvale, CA, United States (U.S. corporation)  
 AI US 6057299 20000502  
 AI US 1996-721690 19960927 (8)  
 RLI Continuation-in-part of Ser. No. US 1995-380916, filed on 30 Jan 1995,  
 now patented, Pat. No. US 5648478 which is a continuation-in-part of  
 Ser. No. US 1994-182247, filed on 13 Jan 1994, now patented, Pat. No. US  
 5830686 And a continuation-in-part of Ser. No. US 1996-669753, filed on  
 26 Jun 1996, now patented, Pat. No. US 5871726 which is a  
 continuation-in-part of Ser. No. US 1995-495034, filed on 27 Jun 1995,  
 now patented, Pat. No. US 5698443  
 DT Utility  
 FS Granted  
 INCL INCLM: 514/044.000  
 INCLM: 536/023.100; 536/024.100; 435/069.100; 435/320.100; 435/325.000;  
 435/455.000; 435/458.000; 424/093.210  
 NCLM: 514/044.000  
 NCLM: 424/093.210; 435/069.100; 435/320.100; 435/325.000; 435/455.000;  
 435/458.000; 536/023.100; 536/024.100  
 IC [7]  
 ICM: A61K048-00  
 EXF 435/320.1; 435/172.3; 435/325; 514/44; 424/93.21; 536/23.1;  
 536/24.1; 935/51; 935/61; 935/63; 935/455; 935/458; 935/69.1  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L9 ANSWER 37 OF 42 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.  
 AN 2000416349 EMBASE  
 TI Adeno-associated virus production of soluble tumor necrosis factor  
 AU receptor neutralizes tumor necrosis factor .alpha. and reduces arthritis.  
 AU Zhang H.-G.; Xie J.; Yang P.; Wang Y.; Xu L.; Liu D.; Hsu H.-C.; Zhou T.;  
 Edwards III C.K.; Mountz J.D.  
 CS Dr. J.D. Mountz, Div. of Clin. Immunol./Rheumatology, Department of  
 Medicine, University of Alabama, 701 South 19th Street, Birmingham, AL  
 35294, United States. john.mountz@ccc.uab.edu (2431-2442).  
 SO Human Gene Therapy, (20 Nov 2000) 11/17 (2431-2442).  
 Reirs: 33  
 ISSN: 1043-0342 CODEN: RCTHE3  
 CY United States  
 DT Journal: Article  
 FS 031 Arthritis and Rheumatism  
 LA Drug Literature Index  
 SL English  
 L9 ANSWER 38 OF 42 USPATFULTL  
 AN 1998:138874 USPATFULTL  
 TI Adeno-associated viral (AAV) liposomes and methods related thereto  
 IN Philip, Ramila, Redwood City, CA, United States  
 IN Lebkowski, Jane, Portola Valley, CA, United States  
 PA Rhone-Poulenc Rorer Pharmaceuticals Inc., Collegeville, PA, United  
 States (U.S. corporation)  
 PI US 5834441 19981110  
 AI US 1994-305221 19940912 (8)

RLI Continuation-in-part of Ser. No. US 1993-120605, filed on 13 Sep 1993,  
now abandoned  
DT Utility  
FS Granted  
LN.CNT 2059  
INCL INCLM: 514/044.000  
INCLS: 424/093.210; 424/450.000; 435/069.100; 435/172.300; 435/320.100;  
435/325.000; 536/024.100; 935/022.000; 935/034.000; 935/056.000;  
935/060.000; 935/062.000; 935/070.000  
NCLM: 514/044.000  
NCLS: 424/093.210; 424/450.000; 435/069.100; 435/320.100; 435/325.000;  
435/456.000; 536/024.100  
IC [6]  
ICM: A01N063-00  
ICS: A61K048-00; A61K009-127; C12N005-00  
EXF 514/44; 514/2; 435/320.1; 435/172.3; 435/240.2; 435/69.1;  
435/325; 424/93.1; 424/93.21; 424/450; 536/24.1; 935/22; 935/34; 935/56;  
935/60; 935/62; 935/70  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 39 OF 42 USPTAFULL  
AN 1998:134840 USPTAFULL.  
TI Tissue-specific enhancer active in prostate  
IN Henderson, Daniel R., Palo Alto, CA, United States  
PA Calydon, Menlo Park, CA, United States (U.S. corporation)  
PI US 5830686 19981103  
AI US 1994-182247 19940113 (8)  
DT Utility  
FS Granted  
LN.CNT 1169  
INCL INCLM: 435/069.100  
INCLS: 435/240.200; 435/320.100; 536/024.100  
NCLM: 435/069.100  
NCLS: 435/320.100; 435/455.000; 536/024.100  
IC [6]  
ICM: C12N015-00  
ICS: C12N015-85; C12N015-63; C07H021-04  
EXF 514/44; 536/24.1; 435/320.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 40 OF 42 USPTAFULL  
AN 97:91712 USPTAFULL.  
TI Transgenic arthritic mice expressing a T-cell receptor transgene  
IN Benoist, Christophe O., Strasbourg, France  
PA Mathis, Diane U., Strasbourg, France  
Kouskoff, Valerie, Denver, CO, United States  
Institut National de la Sante et de la Recherche Medicale, Paris, France  
(non-U.S. corporation)  
Centre National de la Recherche Scientifique, Paris, France (non-U.S.  
government)  
Universite Louis Pasteur, Strasbourg 1, Paris, France (non-U.S.  
corporation)  
E.R. Squibb & Sons, Inc., Princeton, NJ, United States (U.S.  
corporation)  
PI US 5675060 19971007  
AI US 1994-246242 19940519 (8)  
DT Utility  
FS Granted  
LN.CNT 2377  
INCL INCLM: 800/002.000  
INCLS: 424/009.200  
NCLM: 800/003.000  
NCLS: 424/009.200; 800/009.000  
IC [6]

ICM: C12N005-00  
ICS: C12P015-00; A61K049-00  
EXF 800/2; 424/9-2  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 41 OF 42 USPTAFULL  
AN 97:6611 USPTAFULL  
TI Methods and compositions for gene therapy for the treatment of defects  
IN in lipoprotein metabolism  
Wilson, James M., Gladwyne, PA, United States  
Kozarsky, Karen, Philadelphia, PA, United States  
Strauss, III, Jerome, Wyndmoor, PA, United States  
The Trustees of the University of Pennsylvania, Philadelphia, PA, United  
States (U.S. corporation)  
PI US 5652224 19970729  
AI US 1995-393734 19950224 (8)  
DT Utility  
FS Granted  
LN.CNT 2079  
INCL INCLM: 514/044.000  
INCLS: 424/093.210; 435/172.300; 435/320.100; 435/325.000; 435/354.000;  
435/366.000; 435/369.000; 435/370.000  
NCLM: 514/044.000  
NCLS: 424/093.210; 435/320.100; 435/325.000; 435/354.000; 435/366.000;  
435/369.000; 435/370.000; 435/456.000  
IC [6]  
ICM: A61K048-00  
ICS: C12N015-00  
EXF 424/93.21; 435/320.1; 435/240.2; 435/172.3; 435/240.1; 514/44; 514/2;  
536/22.1; 530/350  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 42 OF 42 USPTAFULL  
AN 97:61806 USPTAFULL  
TI Tissue-specific enhancer active in prostate  
IN Henderson, Daniel R., 769 Garland Dr., Palo Alto, CA, United States  
PI US 5648478 19970715  
AI US 1995-380916 19950130 (8)  
RLI Continuation-in-part of Ser. No. US 1994-182247, filed on 13 Jan 1994  
DT Utility  
FS Granted  
LN.CNT 1499  
INCL INCLM: 536/241.000  
INCLS: 435/320.100  
NCLM: 536/024.100  
NCLS: 435/320.100  
IC [6]  
ICM: C07H021-04  
ICS: C12N015-63  
EXF 514/44; 536/24.1; 435/320.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his  
(FILE 'HOME' ENTERED AT 09:10:35 ON 11 JUL 2002)  
FILE 'MEDLINE, CANCERLIT, CAPLUS, USPTAFULL, BIOSIS, EMBASE, CONFSCI'  
ENTERED AT 09:11:14 ON 11 JUL 2002  
538 S IMMUNOGEN? (S) TRANSGENE?  
L1 52 S L1 AND ALLOGEN?  
L2 27 S L2 AND PROMOT?  
L3 11 S L3 NOT PY>1998  
L4

L5 1 S L2 AND CELL? (A) THERAP?

L6 12 S L1 AND CELL? (A) VACCINE

L7 58 S L1 AND FIBROBLAST

L8 42 S L7 AND ADMINSTR?

L9 42 DUP REM L8 (0 DUPLICATES REMOVED)

=> 8 cell? (a) immunogen?

2 FILES SEARCHED...

6 FILES SEARCHED...

L10 1688 CELL? (A) IMMUNOGEN?

=> s 110 and transgene

L11 30 L10 AND TRANSGENE

=> d 111 1-30

L11 ANSWER 1 OF 30 CAPLUS COPYRIGHT 2002 ACS

AN 2002:249967 CAPLUS

DN 136:278130

TI Cellular immunogens comprising cognate proto-oncogenes for use in cancer vaccines

IN Halpern, Michael S.; England, James M.

PA Philadelphia Health and Educational Corporation, USA

SO U.S., 35 pp., Cont.-in-part of U.S. Ser. No. 101,226, abandoned.

DT Patent

LA English

FAN CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6365151	B1	20020402	US 1998-167322	19981007
WO 9725860	A1	19970724	WO 1997-US582	19970113
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, MY, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, ST, TM, TR, TT, UA, US, UZ, VN, AM, AZ, BL, BR, CG, CZ, MD, RU, TJ, TM				
RM: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GN, ML, MR, NE, SN, TD, TG				
PRAI US 1996-10262P	P	19960119		
US 1997-US582	A2	19970113		
WO 1998-101226	B2	19980702		

RE. CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 2 OF 30 CAPLUS COPYRIGHT 2002 ACS

AN 2000:84650 CAPLUS

DN 132:136415

TI Allogeneic cellular immunogens useful as cancer vaccines

IN Halpern, Michael S.; England, James M.

PA Allegheny University of the Health Sciences, USA

SO PCT Int. Appl., 77 pp.

DT Patent

LA English

FAN CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000004927	A1	20000203	WO 1999-US15594	19990708
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GR, GM, GU, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,				

MN, MM, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RM: CH, CM, CN, KE, LS, MW, SD, SL, SZ, UG, ZM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IL, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, CA, GN, GM, ME, MK, NE, SN, TD, TG

AU 9949819

EP 1100544

AT 20000214

AL 20010523

EP 1999-933855

19990708

19990708

PRAI US 1998-93965P

WO 1999-US15594

W 19990708

RE. CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 3 OF 30 CAPLUS COPYRIGHT 2002 ACS

AN 1998:542991 CAPLUS

DN 129:160641

TI Cancer immunotherapy with semi-allogeneic cells

IN Cohen, Edward P.

PA USA

SO PCT Int. Appl., 120 pp.

DT Patent

LA English

FAN CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9833527	A2	19980806	WO 1998-US1824	19980130
WO 9833527	A3	19981105		
W: CA, JP				
RM: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1012240	A2	20000628	EP 1998-904782	19980130
R: AT, BE, CH, DE, ES, FR, GB, IT, IL, NL, IE				
US 6187307	B1	20010213	US 1998-16528	19980130
JP 2001522226	T2	20011113	JP 1998-531112	19980130
PRAI US 1997-3620P	P	19970131		
WO 1998-US1824	W	19980130		

L11 ANSWER 4 OF 30 CAPLUS COPYRIGHT 2002 ACS

AN 1998:181516 CAPLUS

DN 128:293868

TI Resistance to melanoma in mice immunized with semiallogeneic fibroblasts transfected with DNA from mouse melanoma cells

AU Dep. of Zoeten, Edwin F.; Carr-Brendel, Victoria; Cohen, Edward P.

CS Dep. of Microbiology and Immunology, University of Illinois at Chicago, Chicago, IL, 60612, USA

SO Journal of Immunology (1998), 160(6), 2915-2922

CODEN: JOIMA3; ISSN: 0022-1767

PB American Association of Immunologists

DT Journal

LA English

L11 ANSWER 5 OF 30 CAPLUS COPYRIGHT 2002 ACS

AN 1997:499063 CAPLUS

DN 127:160563

TI Cellular proto-oncogene immunogens for cancer vaccines

IN Halpern, Michael S.; England, James M.

PA Allegheny University of the Health Sciences, USA; Halpern, Michael S.; England, James M.

SO PCT Int. Appl., 81 pp.

DT Patent

LA English

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9725860	A1	19970724	MO 1997-US582	19970113
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GN, GT, ML, MR, NE, SN, TD, TG	AA	19970724	CA 1997-2241952	19970113
AU 9716992	A1	19970811	AU 1997-16992	19970113
AU 713356	B2	20000323		
EP 923284	A1	19990623	EP 1997-902934	19970113
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI	T2	20010213	JP 1997-526124	19970113
JP 2001501909	B1	20020402	US 1998-167322	19981007
US 6365151	P	19960119		
PRAI US 1996-10262P				
US 1997-US582				
US 1998-101226	B2	19980702		
L11 ANSWER 6 OF 30 CAPLUS COPYRIGHT 2002 ACS				
AN 1993:493480 CAPLUS				
DN 119:93480				
TI Superantigen-induced peripheral tolerance inhibits T cell responses to immunogenic peptides in TCR (beta-chain) transgenic mice				
AU Perkins, David L.; Wang, Yunsheng; Ho, Sai Sun; Wiens, Garth R.; Seidman, J. G.; Rimm, Ilona J.				
CS Lab. Immunogenet. Transplant., Brigham Women's Hosp., Boston, MA, 02115, USA				
SO J. Immunol. (1993), 150(10), 4284-91				
DT CODEN: JOIMAJ, ISSN: 0022-1767				
LA English				
L11 ANSWER 7 OF 30 USPATFULL				
AN 2002:166378 USPATFULL				
TI Minimal adenovirus mediated recombinant vaccine				
IN Fang, Xiangming, San Diego, CA, UNITED STATES				
Gallichan, Scott, San Diego, CA, UNITED STATES				
Zhang, Wei-Wei, San Diego, CA, UNITED STATES				
Wong, Strael, Flossie, San Diego, CA, UNITED STATES				
Sauter, Sybille, Del Mar, CA, UNITED STATES				
PI US 2002088014 A1 20020704				
AI US 2001-974206 A1 20011010 (9)				
RI Continuation-in-part of Ser. No. US 1997-866403, filed on 30 May 1997, PENDING Continuation-in-part of Ser. No. US 1997-791218, filed on 31 Jan 1997, ABANDONED Continuation-in-part of Ser. No. US 1996-658961, filed on 31 May 1996, PENDING				
PRAI US 2000-239224P 20001010 (60)				
US 2000-241625P 20001019 (60)				
DT Utility				
FS APPLICATION				
LN.CNT 4062				
INCL INCLM: 800/008.000				
INCL INCLM: 435/320.100; 435/456.000; 435/235.100				
NCL INCLM: 800/008.000				
NCLM: 435/320.100; 435/456.000; 435/235.100				
IC [7]				
ICM: A01K067-00				
ICS: C12N015-867; C12N015-861; C12N007-00; C12N007-01				

L11 ANSWER 8 OF 30 USPATFULL

AN 2002:144239 USPATFULL

TI Tumor antigens and CTL clones isolated by a novel procedure

IN Luiten, Rosalie, Brussels, BELGIUM

Dufour, Marie-Therese, Brussels, BELGIUM

Demotte, Nathalie, Brussels, BELGIUM

van der Bruggen, Pierre, Brussels, BELGIUM

Cornelius, Guy, Brussels, BELGIUM

Sercoebant, Vincent, Brussels, BELGIUM

Lurquin, Christophe, Brussels, BELGIUM

Boon-Fallier, Thierry, Brussels, BELGIUM

Ludwig Institute for Cancer Research, New York, NY, United States (U.S. corporation)

PA Universite Catholique de Louvain, Louvain-la-Neuve, BELGIUM (non-U.S. corporation)

PI US 6407063 B1 20020618

AI US 1998-165863 19981002 (9)

DT Utility

FS GRANTED

LN.CNT 1456

INCL INCLM: 514/013.000

INCL INCLM: 530/326.000; 530/328.000; 514/015.000

NCL INCLM: 514/013.000

NCLM: 530/326.000; 530/328.000; 514/015.000

IC [7]

ICM: A61K038-08

ICS: A61K038-10; C07K007-06; C07K007-08

EXP 514/15; 514/13; 530/328; 530/326

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 9 OF 30 USPATFULL

AN 2002:133493 USPATFULL

TI 98P703: homeodomain protein highly expressed in various cancers

IN Chailita-Eid, Pia M., Encino, CA, UNITED STATES

Hubert, Rene S., Los Angeles, CA, UNITED STATES

Faris, Mary, Los Angeles, CA, UNITED STATES

Afar, Daniel E.H., Brisbane, CA, UNITED STATES

Levin, Elana, Los Angeles, CA, UNITED STATES

Mitchell, Steve Chappell, Santa Monica, CA, UNITED STATES

Jakobovits, Aya, Beverly Hills, CA, UNITED STATES

PI US 2002068345 A1 20020606

AI US 2001-866359 A1 20010524 (9)

PRAI US 2000-207138P 20000524 (60)

DT Utility

FS APPLICATION

LN.CNT 6137

INCL INCLM: 435/183.000

INCL INCLM: 435/325.000; 435/320.100; 435/069.100

NCL INCLM: 435/183.000

NCLM: 435/325.000; 435/320.100; 435/069.100

IC [7]

ICM: C12P021-02

ICS: C12N009-00; C12N005-06

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 10 OF 30 USPATFULL

AN 2002:106269 USPATFULL

TI GTP-binding protein useful in treatment and detection of cancer

IN Faris, Mary, Los Angeles, CA, UNITED STATES

Chailita-Eid, Pia M., Encino, CA, UNITED STATES

Raitano, Arthur B., Los Angeles, CA, UNITED STATES

Mitchell, Steve Chappell, Santa Monica, CA, UNITED STATES

Afar, Daniel E.H., Brisbane, CA, UNITED STATES

PI Jakobovics, Aya, Beverly Hills, CA, UNITED STATES  
 AI US 2002055478 A1 20020509  
 PRAI US 2001-834765 A1 20010412 (9)  
 DT US 2000-196647P 20000412 (60)  
 FS APPLICATION  
 LN CNT 5003  
 INCL INCLM: 514/044.000  
 NCL INCLM: 435/006.000; 435/007.230  
 NCLM: 514/044.000  
 NCLS: 435/006.000; 435/007.230  
 IC [7]  
 ICM: A61K048-00  
 ICS: C120001-68; G01N033-574  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L11 ANSWER 11 OF 30 USPATFULT  
 AN 2002:84909 USPATFULT  
 TI Methods and compositions for co-stimulation of immunological responses to peptide antigens  
 IN Khleif, Samir, Silver Spring, MD, UNITED STATES  
 PI Berzofsky, Jay, Bethesda, MD, UNITED STATES  
 AI US 2002044948 A1 20020418  
 PRAI US 2001-810310 A1 20010314 (9)  
 DT US 2000-189396P 20000315 (60)  
 FS APPLICATION  
 LN CNT 3104  
 INCL INCLM: 424/234.100  
 NCL INCLM: 424/184.100; 530/350.000  
 NCLM: 424/234.100  
 NCLS: 424/184.100; 530/350.000  
 IC [7]  
 ICM: A61K039-00  
 ICS: A61K039-18; A61K039-02; C07K001-00; C07K014-00; C07K017-00  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L11 ANSWER 12 OF 30 USPATFULT  
 AN 2002:78215 USPATFULT  
 TI Cell fusions and methods of making and using the same  
 IN Nicolette, Charles, Framingham, MA, UNITED STATES  
 PI Roberts, Bruce L., Southboro, MA, UNITED STATES  
 RLI Gong, Jianlin, Brookline, MA, UNITED STATES  
 PI Kufe, Donald, Wellesley, MA, UNITED STATES  
 AI US 2002041868 A1 20020411  
 DT US 2001-782492 A1 20010212 (9)  
 FS Continuation-in-part of Ser. No. US 2000-618917, filed on 18 Jul 2000,  
 PENDING Continuation of Ser. No. US 1998-60603, filed on 15 Apr 1998,  
 ABANDONED Continuation of Ser. No. US 2000-642701, filed on 12 Aug 2000,  
 UNKNOWN A 371 of International Ser. No. WO 1999-US1464, filed on 25 Jan 1999, UNKNOWN  
 PRAI US 1997-43609P 19970415 (60)  
 AI US 2000-181822P 20000211 (60)  
 DT US 2000-184687P 20000224 (60)  
 FS US 1998-80041P 19980331 (60)  
 DT US 1998-88357P 19980126 (60)  
 FS APPLICATION  
 LN CNT 3318  
 INCL INCLM: 424/093.210  
 NCL INCLM: 424/277.100; 435/449.000  
 NCLM: 424/093.210  
 NCLS: 424/277.100; 435/449.000  
 IC [7]

ICM: A61K048-00  
 ICS: A61K039-00; C12N005-08  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L11 ANSWER 13 OF 30 USPATFULT  
 AN 2002:69599 USPATFULT  
 TI Cellular immunogens comprising cognate proto-oncogenes  
 IN Halpern, Michael S, West Newton, MA, United States  
 PA England, James M, Media, PA, United States  
 PA Philadelphia Health and Educational Corporation, Philadelphia, PA,  
 PI United States (U.S. corporation)  
 AI US 6365151 B1 20020402  
 DT US 1998-167322 B1 19981007 (9)  
 RLI Continuation-in-part of Ser. No. US 1998-101226, filed on 2 Jul 1998,  
 now abandoned Continuation-in-part of Ser. No. WO 1997-US582, filed on 13 Jan 1997  
 PRAI US 1996-10262P 19960119 (60)  
 DT US 1996-10262P 19960119 (60)  
 FS GRANTED  
 LN CNT 1838  
 INCL INCLM: 424/093.210  
 NCL INCLM: 424/093.200; 435/325.000; 435/320.100; 514/044.000  
 NCLM: 424/093.210  
 NCLS: 424/093.200; 435/320.100; 435/325.000; 514/044.000  
 IC [7]  
 ICM: A61K035-00  
 ICS: A61K048-00; C12N015-85; C12N015-63  
 EXF 435/325; 435/320.1; 424/93.2; 424/93.21; 514/44  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L11 ANSWER 14 OF 30 USPATFULT  
 AN 2002:54318 USPATFULT  
 TI Porcine neural cells and their use in treatment of neurological deficits due to neurodegenerative diseases  
 IN Fraser, Thomas, Newton, MA, UNITED STATES  
 PA Dinmore, Jonathan, Brookline, MA, UNITED STATES  
 PI Diacrin, Inc. (U.S. corporation)  
 AI US 2002031497 A1 20020314  
 PRAI US 2001-843270 A1 20010428 (9)  
 DT Division of Ser. No. US 1995-424855, filed on 19 Apr 1995, GRANTED, Pat.  
 RLI No. US 6277372 Continuation-in-part of Ser. No. US 1994-336856, filed on 8 Nov 1994, ABANDONED  
 DT US 1994-336856  
 FS APPLICATION  
 LN CNT 3959  
 INCL INCLM: 424/093.700  
 NCL INCLM: 435/325.000  
 NCLM: 424/093.700  
 NCLS: 435/325.000  
 IC [7]  
 ICM: A61K045-00  
 ICS: C12N005-06  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L11 ANSWER 15 OF 30 USPATFULT  
 AN 2002:24275 USPATFULT  
 TI Herpes virus vectors and their uses  
 IN Bourneil, Michael Edward Griffith, Cambridge, UNITED KINGDOM  
 PI Brenner, Malcolm Keith, Memphis, TN, United States  
 PA Dilloo, Dagmar, Dusseldorf, GERMANY, FEDERAL REPUBLIC OF  
 Ioglis, Stephen Charles, Cambridge, UNITED KINGDOM  
 PA Cantab pharmaceutical Research Limited, Cambridge, UNITED KINGDOM (non-U.S. corporation)

St. Jude Children's Research Hospital, Memphis, TN, United States (U.S. corporation)

PI US 6344445 B1 20020205  
 AI US 1996-734054 19961018 (8)  
 PRAI US 1995-5649P 19951019 (60)  
 DT Utility  
 FS GRANTED  
 LN.CNT 1789  
 INCL INCLM: 514/044.000  
 INCLS: 435/456.000  
 NCLM: 514/044.000  
 NCLS: 435/456.000  
 IC [7]  
 ICM: A61K031-70  
 ICS: C12N015-86  
 EXF 514/44; 435/456; 435/472  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 16 OF 30 USPTAFULL  
 AN 2002:19216 USPTAFULL  
 TI Nucleotide and deduced amino acid sequences of tumor gene Int6  
 IN Marchetti, Antonio, Viareggio, ITALY  
 Butitta, Piamma, Viareggio, ITALY  
 Smith, Gilbert H., Falls Church, VA, United States  
 Callahan, Robert, Alexandria, VA, United States  
 PA The United States of America as represented by the Department of Health  
 and Human Services, Washington, DC, United States (U.S. corporation)  
 PI US 6342392 B1 20020129  
 AI US 1999-378842 19990823 (9)  
 RLI Division of Ser. No. US 875847 Continuation-in-part of Ser. No. US  
 1995-385998, filed on 9 Feb 1995, now abandoned  
 DT Utility  
 FS GRANTED  
 LN.CNT 2076  
 INCL INCLM: 436/063.000  
 INCLS: 436/086.000; 435/006.000  
 NCLM: 436/063.000  
 NCLS: 435/006.000; 436/086.000  
 IC [7]  
 ICM: G01N033-48  
 ICS: G01N033-00; C12O001-68  
 EXF 514/12; 436/63; 436/86; 435/6  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 17 OF 30 USPTAFULL  
 AN 2002:16585 USPTAFULL  
 TI Porcine neural cells and their use in treatment of neurological deficits  
 IN due to neurodegenerative diseases  
 Isaacson, Ole, Cambridge, MA, UNITED STATES  
 Dinamore, Jonathan, Brookline, MA, UNITED STATES  
 PA Diacrin, Inc. (U.S. corporation)  
 PI US 2002009461 A1 20020124  
 AI US 2001-847881 A1 20010502 (9)  
 RLI Division of Ser. No. US 1995-554779, filed on 7 Nov 1995, GRANTED. Pat.  
 No. US 6258353 Continuation-in-part of Ser. No. US 1995-424851, filed on  
 19 Apr 1995, GRANTED. Pat. No. US 6294383 Continuation-in-part of Ser.  
 No. US 1994-336856, filed on 8 Nov 1994, ABANDONED  
 DT Utility  
 FS APPLICATION  
 LN.CNT 5037  
 INCL INCLM: 424/193.100  
 INCLS: 424/093.700; 435/325.000  
 NCLM: 424/193.100  
 NCLS: 424/093.700; 435/325.000

IC [7]  
 ICM: A61K039-385  
 ICS: C12N005-06; A61K045-00  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 18 OF 30 USPTAFULL  
 AN 2002:13790 USPTAFULL  
 TI Superantigen based methods and compositions for treatment of diseases  
 IN Terman, David Stephen, 3183 Palmero Way, Pebble Beach, CA, United States  
 93953  
 PI US 6340461 B1 20020122  
 AI US 1997-992877 19970217 (8)  
 PRAI US 1996-33172P 19961217 (60)  
 DT US 1997-44074P 19970417 (60)  
 DT Utility  
 FS GRANTED  
 LN.CNT 5893  
 INCL INCLM: 424/193.100  
 INCLS: 424/192.100; 424/194.100; 424/277.100; 424/278.100; 424/280.100;  
 424/282.100; 435/068.100; 435/069.100; 435/069.300; 435/069.700  
 NCLM: 424/193.100  
 NCLS: 424/192.100; 424/194.100; 424/277.100; 424/278.100; 424/280.100;  
 424/282.100; 435/068.100; 435/069.100; 435/069.300; 435/069.700  
 IC [7]  
 ICM: A61K039-385  
 ICS: A61K039-00; A61K039-39; A61K045-00; C12N015-09; C12N015-12;  
 C12N015-62; C12N015-63  
 EXF 424/277.1; 424/193.1; 424/194.1; 424/192.1; 424/278.1; 424/280.1;  
 424/282.1; 435/68.1; 435/69.7; 435/69.3; 435/69.1  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 19 OF 30 USPTAFULL  
 AN 2001:205415 USPTAFULL  
 TI ADENOVIRUS-BASED METHODS, AND CELLS, USEFUL FOR THE EXPRESSION OF  
 IN NUCLEIC ACID SEQUENCES  
 GRAHAM, FRANK L., HAMILTON, Canada  
 ANTON, MARTINA, VATERSTEIN, Germany, Federal Republic of  
 RUDNICKI, MICHAEL A., DUNDAS, Canada  
 PI US 2001041173 A1 20011115  
 AI US 1999-251955 A1 19990217 (9)  
 RLI Continuation-in-part of Ser. No. US 1995-473168, filed on 7 Jun 1995,  
 UNKNOWN  
 DT Utility  
 FS APPLICATION  
 LN.CNT 1227  
 INCL INCLM: 424/093.210  
 INCLS: 536/023.100; 435/456.000; 435/465.000; 435/320.100; 514/044.000  
 NCLM: 424/093.210  
 NCLS: 536/023.100; 435/456.000; 435/465.000; 435/320.100; 514/044.000  
 IC [7]  
 ICM: A61K048-00  
 ICS: C07H021-04; C12N015-87  
 EXF 514/12; 436/63; 436/86; 435/6  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 20 OF 30 USPTAFULL  
 AN 2001:167936 USPTAFULL  
 TI Hepatitis therapeutics  
 IN Jolly, Douglas J., Leucadia, CA, United States  
 Chang, Stephen M. W., Poway, CA, United States  
 Lee, William T. L., Carlsbad, CA, United States  
 Townsend, Kay, Encinitas, CA, United States  
 O'Dea, Joanne, La Jolla, CA, United States  
 PA Chiron Corporation, Emeryville, CA, United States (U.S. corporation)  
 PI US 6297048 B1 20011002

AI US 1995-483511 19950607 (8)  
 RLI Continuation-in-part of Ser. No. US 1995-374414, filed on 19 Jan 1995,  
 now abandoned Continuation-in-part of Ser. No. US 1994-286829, filed on  
 5 Aug 1994, now abandoned Continuation-in-part of Ser. No. US  
 1993-102132, filed on 4 Aug 1993, now abandoned Continuation-in-part of  
 Ser. No. US 1993-32385, filed on 17 Mar 1993, now abandoned  
 Continuation-in-part of Ser. No. US 1992-830417, filed on 4 Feb 1992,  
 now abandoned

DT Utility  
 FS GRANTED  
 LN CNT 3732  
 INCL INCLM: 435/320.100  
 INCLS: 435/069.300  
 NCLM: 435/320.100  
 NCL NCLS: 435/069.300

IC ICM: C12N015-63  
 ICS: C12P021-02  
 435/69.1; 435/69.3; 435/320.1; 424/228.1  
 EXF 435/69.1; 435/69.3; 435/320.1; 424/228.1  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 21 OF 30 USPTATFUL  
 AN 2001:163053 USPTATFUL  
 TI Porcine neural cells and their use in treatment of neurological deficits  
 due to neurodegenerative diseases  
 IN Isaacson, Ole, Cambridge, MA, United States  
 PA The McLean Hospital Corporation, Belmont, MA, United States (U.S.  
 corporation)  
 PI Diacrin, Inc., Charlestown, MA, United States (U.S. corporation)  
 AI US 6294383 B1 20010925  
 US 1995-424851 19950419 (8)  
 RLI Continuation-in-part of Ser. No. US 1994-336856, filed on 8 Nov 1994,  
 now abandoned

DT Utility  
 FS GRANTED  
 LN CNT 4123  
 INCL INCLM: 435/379.000  
 INCLS: 435/325.000  
 NCLM: 435/379.000  
 NCL NCLS: 435/325.000

IC ICM: C12N005-00  
 ICS: C12N005-02  
 435/240.1; 435/240.2; 435/325; 435/379  
 EXF 435/240.1; 435/240.2; 435/325; 435/379  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 22 OF 30 USPTATFUL  
 AN 2001:136181 USPTATFUL  
 TI Porcine neural cells and their use in treatment of neurological deficits  
 due to neurodegenerative diseases  
 IN Fraser, Thomas, Newton, MA, United States  
 PA Diacrin, Inc., Charlestown, MA, United States (U.S. corporation)  
 AI US 6277372 B1 20010821  
 US 1995-424855 19950419 (8)  
 RLI Continuation-in-part of Ser. No. US 1994-336856, filed on 8 Nov 1994,  
 now abandoned

DT Utility  
 FS GRANTED  
 LN CNT 4112  
 INCL INCLM: 424/093.700  
 INCLS: 424/093.100; 435/325.000  
 NCLM: 424/093.700

IC NCLS: 424/093.100; 435/325.000  
 ICM: A01N063-00  
 ICS: C12N005-02; C12N005-06  
 435/325; 424/93.1; 424/93.7  
 EXF 435/325; 424/93.1; 424/93.7  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 23 OF 30 USPTATFUL  
 AN 2001:107439 USPTATFUL  
 TI Porcine neural cells and their use in treatment of neurological deficits  
 due to neurodegenerative diseases  
 IN Isaacson, Ole, Cambridge, MA, United States  
 PA Diacrin, Inc., Charlestown, MA, United States (U.S. corporation)  
 AI US 6258153 B1 20010710  
 US 1995-554779 19951107 (8)  
 RLI Continuation-in-part of Ser. No. US 1995-424851, filed on 19 Apr 1995  
 Continuation-in-part of Ser. No. US 1994-336856, filed on 8 Nov 1994,  
 now abandoned

DT Utility  
 FS GRANTED  
 LN CNT 5157  
 INCL INCLM: 424/093.100  
 INCLS: 424/093.700; 424/130.100; 424/143.100; 424/809.000; 435/325.000;  
 435/368.000  
 NCLM: 424/093.100  
 NCL NCLS: 424/093.700; 424/130.100; 424/143.100; 424/809.000; 435/325.000;  
 435/368.000

IC ICM: A01N003-00  
 ICS: C12N015-85; C12N015-86; A61K039-395  
 424/93.7; 424/93.1; 424/130.1; 424/143.1; 424/809; 435/325; 435/368  
 EXF 424/93.7; 424/93.1; 424/130.1; 424/143.1; 424/809; 435/325; 435/368  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 24 OF 30 USPTATFUL  
 AN 2001:102615 USPTATFUL  
 TI Nucleotide and deduced amino acid sequences of tumor gene Int6  
 IN Marchetti, Antonio, Viareggio, Italy  
 PA Buticita, Fiama, Viareggio, Italy  
 Smith, Gilbert H., Falls Church, VA, United States  
 Callahan, Robert, Alexandria, VA, United States  
 PA The United States of America as represented by the Department of Health  
 and Human Services, Washington, DC, United States (U.S. government)  
 PI US 6255105 B1 20010703  
 US 9624672 19970815  
 AI US 1997-875847 19970925 (8)  
 WO 1996-US1884 19960209  
 PCT 371 date  
 19970925 PCT 102(e) date  
 19970925

RLI Continuation-in-part of Ser. No. US 1995-385998, filed on 9 Feb 1995,  
 now abandoned

DT Utility  
 FS GRANTED  
 LN CNT 1789  
 INCL INCLM: 435/325.000  
 INCLS: 435/252.300; 435/320.100; 435/069.100  
 NCLM: 435/325.000  
 NCL NCLS: 435/069.100; 435/252.300; 435/320.100

IC ICM: C12N005-00  
 ICS: C12N015-00; C12N001-20; C12P021-06  
 435/69.1; 435/320.1; 435/325; 435/252.3; 435/366; 435/371; 435/252.8  
 EXF 435/69.1; 435/320.1; 435/325; 435/252.3; 435/366; 435/371; 435/252.8  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 25 OF 30 USPATFULL.  
 AN 2001:40268 USPATFULL.  
 TI Porcine cortical cells and their use in treatment of neurological  
 IN deficits due to neurodegenerative diseases  
 PA Dinmore, Jonathan, Brookline, MA, United States  
 PI Diarrin, Inc., Charlestown, MA, United States (U.S. corporation)  
 AI US 6204053 B1 20010320  
 RLI US 1995-424856 19950419 (8)  
 Continuation-in-part of Ser. No. US 1994-336856, filed on 8 Nov 1994,  
 now abandoned  
 DT Utility  
 FS Granted  
 INCL INCLM: 435/325.000  
 INCLS: 424/093.700; 435/374.000  
 NCLM: 435/325.000  
 NCLS: 424/093.700; 435/374.000  
 IC [7]  
 ICM: C12N005-00  
 EXP 435/240.2; 435/325; 435/374; 424/93.7  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 26 OF 30 USPATFULL.  
 AN 2000:146162 USPATFULL.  
 TI Isolated and modified porcine cerebral cortical cells  
 IN Dinmore, Jonathan, Brookline, MA, United States  
 PA Diarrin, Inc., Charlestown, MA, United States (U.S. corporation)  
 PI US 6140116 20001031  
 AI US 1995-551820 19951107 (8)  
 RLI Continuation-in-part of Ser. No. US 1995-424856, filed on 19 Apr 1995  
 which is a continuation-in-part of Ser. No. US 1995-336856, filed on 8  
 Nov 1995, now abandoned  
 DT Utility  
 FS Granted  
 INCL INCLM: 435/325.000  
 INCLS: 435/374.000; 424/093.700  
 NCLM: 435/325.000  
 NCLS: 424/093.700; 435/374.000  
 IC [7]  
 ICM: C12N005-00  
 EXP 435/325; 435/374; 435/93.7  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 27 OF 30 USPATFULL.  
 AN 2000:124543 USPATFULL.  
 TI Compositions and methods for enhanced tumor cell immunity in vivo  
 IN Fakhrai, Habib, La Jolla, CA, United States  
 PA Dorigo, Oliver, San Diego, CA, United States  
 PI Sobol, Robert E., Rancho Santa Fe, CA, United States  
 RLI Sidney Kimmel Cancer Center, San Diego, CA, United States (U.S.  
 corporation)  
 AI US 6120763 20000919  
 RLI US 1997-968986 19971112 (8)  
 Continuation of Ser. No. US 1994-276694, filed on 18 Jul 1994, now  
 patented, Pat. No. US 5772995  
 DT Utility  
 FS Granted  
 INCL INCLM: 424/093.210  
 INCLS: 435/320.100; 435/069.100; 435/325.000; 435/007.230; 435/091.100;  
 435/091.400  
 NCLM: 424/093.210  
 NCLS: 435/007.230; 435/069.100; 435/091.100; 435/091.400; 435/320.100;

IC [7]  
 ICM: A01N063-00  
 EXP 514/44; 424/93.21; 435/320.1; 435/172.3; 435/325; 435/57; 435/62;  
 435/71; 435/52; 435/55; 435/69.1; 435/7.23; 435/91.1; 435/91.4  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 28 OF 30 USPATFULL.  
 AN 2000:109594 USPATFULL.  
 TI XAF genes and polypeptides: methods and reagents for modulating  
 IN apoptosis  
 IN Korneluk, Robert G., Ottawa, Canada  
 Tamai, Katsuyuki, Nagano, Japan  
 Iliston, Peter, Ottawa, Canada  
 PA MacKenzie, Alexander E., Ottawa, Canada  
 PI Apoptogen Inc., Ottawa, Canada (non-U.S. corporation)  
 AI US 6107088 20000822  
 PRAI US 1998-100391 19980619 (9)  
 AI US 1997-52402P 19970714 (60)  
 US 1997-54491P 19970801 (60)  
 US 1997-56338P 19970818 (60)  
 DT Utility  
 FS Granted  
 INCL INCLM: 435/325.000  
 INCLS: 536/023.100; 536/023.500; 536/024.100; 536/024.500; 435/320.100;  
 435/375.000; 435/377.000  
 NCLM: 435/325.000  
 NCLS: 435/325.000  
 IC [7]  
 ICM: C12N015-85  
 EXP 435/325; 435/243; 435/410; 435/69.1; 435/69.2; 435/320.1; 435/353;  
 435/363; 435/375; 435/377; 536/23.1; 536/23.5; 536/24.5; 536/24.1  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 29 OF 30 USPATFULL.  
 AN 1998:75152 USPATFULL.  
 TI Compositions and methods for enhanced tumor cell immunity in vivo  
 IN Fakhrai, Habib, La Jolla, CA, United States  
 PA Dorigo, Oliver, San Diego, CA, United States  
 PI Sobol, Robert E., Rancho Santa Fe, CA, United States  
 RLI Sidney Kimmel Cancer Center, San Diego, CA, United States (U.S.  
 corporation)  
 AI US 5772995 19980630  
 AI US 1994-276694 19940718 (8)  
 DT Utility  
 FS Granted  
 INCL INCLM: 424/093.210  
 INCLS: 435/009.000; 435/007.230; 435/069.100; 435/091.100; 435/091.400;  
 435/325.000; 530/389.700  
 NCLM: 424/093.210  
 NCLS: 435/006.000; 435/007.230; 435/069.100; 435/091.100; 435/091.400;  
 435/325.000; 530/389.700  
 IC [6]  
 ICM: A61K038-54  
 EXP 424/93.21; 435/6; 435/7.23; 435/69.1; 435/91.1; 435/91.4; 435/325;  
 530/389.7; 935/23; 935/24; 935/52; 935/55; 935/59; 935/62; 935/76;  
 935/78  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 30 OF 30 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.



AN 2002:281018 BIOSIS  
DN PREV200200281018  
TI Cellular immunogens comprising cognate proto-oncogenes.  
AU Halpern, Michael S (1); England, James M  
CS (1) West Newton, MA USA  
ASSIGNEE: Philadelphia Health and Educational Corporation, Philadelphia,  
PA, USA  
PI US 6365151 April 02, 2002  
SO Official Gazette of the United States Patent and Trademark Office Patents,  
(Apr. 2, 2002) Vol. 1257, No. 1, pp. No Pagination.  
http://www.uspto.gov/web/menu/patdata.html. e-file.  
ISSN: 0098-1133.  
DT Patent  
LA English

=> FILE STINGUIDE  
COST IN U.S. DOLLARS  
FULL ESTIMATED COST 131.90 132.11  
FILE 'STINGUIDE' ENTERED AT 09:30:40 ON 11 JUL 2002  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE  
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSENTRUM KARLSRUHE  
FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: Jul 5, 2002 (20020705/UP).

=> d hsi  
YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS, USPATFULL, BIOSIS' - CONTINUE? (Y)/N:n

=> d his

(FILE 'HOME' ENTERED AT 09:10:35 ON 11 JUL 2002)  
FILE 'MEDLINE, CANCERLIT, CAPLUS, USPATFULL, BIOSIS, EMBASE, CONFSCI'  
ENTERED AT 09:11:14 ON 11 JUL 2002  
L1 538 S L1 AND ALLOGEN?  
L2 52 S L1 AND ALLOGEN?  
L3 27 S L2 AND PROMOT?  
L4 11 S L3 NOT PY>1998  
L5 1 S L2 AND CELL? (A) THERAP?  
L6 12 S L1 AND CELL? (A) VACCINE  
L7 58 S L1 AND FIBROBLAST  
L8 42 S L7 AND ADMINIST?  
L9 42 DUP REM L8 (0 DUPLICATES REMOVED)  
L10 1688 S CELL? (A) IMMUNOGEN?  
L11 30 S L10 AND TRANSGENE

FILE 'STINGUIDE' ENTERED AT 09:30:40 ON 11 JUL 2002  
=> FILE MEDLINE, CANCERLIT, CAPLUS, USPATFULL, BIOSIS, EMBASE, CONFSCI  
COST IN U.S. DOLLARS  
FULL ESTIMATED COST 131.90 132.11

FILE 'MEDLINE' ENTERED AT 09:36:27 ON 11 JUL 2002  
FILE 'CANCERLIT' ENTERED AT 09:36:27 ON 11 JUL 2002  
FILE 'CAPLUS' ENTERED AT 09:36:27 ON 11 JUL 2002  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)  
FILE 'USPATFULL' ENTERED AT 09:36:27 ON 11 JUL 2002  
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)  
FILE 'BIOSIS' ENTERED AT 09:36:27 ON 11 JUL 2002  
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC. (R)  
FILE 'EMBASE' ENTERED AT 09:36:27 ON 11 JUL 2002  
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.  
FILE 'CONFSCI' ENTERED AT 09:36:27 ON 11 JUL 2002  
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

=> d his

(FILE 'HOME' ENTERED AT 09:10:35 ON 11 JUL 2002)  
FILE 'MEDLINE, CANCERLIT, CAPLUS, USPATFULL, BIOSIS, EMBASE, CONFSCI'  
ENTERED AT 09:11:14 ON 11 JUL 2002  
L1 538 S L1 AND ALLOGEN?  
L2 52 S L1 AND ALLOGEN?  
L3 27 S L2 AND PROMOT?  
L4 11 S L3 NOT PY>1998  
L5 1 S L2 AND CELL? (A) THERAP?  
L6 12 S L1 AND FIBROBLAST  
L7 58 S L1 AND ADMINIST?  
L8 42 S L7 AND ADMINIST?  
L9 42 DUP REM L8 (0 DUPLICATES REMOVED)  
L10 1688 S CELL? (A) IMMUNOGEN?  
L11 30 S L10 AND TRANSGENE

FILE 'STINGUIDE' ENTERED AT 09:30:40 ON 11 JUL 2002

FILE 'MEDLINE, CANCERLIT, CAPLUS, USPATFULL, BIOSIS, EMBASE, CONFSCI'  
ENTERED AT 09:36:27 ON 11 JUL 2002

=> s l10 and oncogene  
L12 64 L10 AND ONCOGENE  
=> dup rem l12  
PROCESSING COMPLETED FOR L12  
L13 52 DUP REM L12 (12 DUPLICATES REMOVED)  
=> d l13 1-52

L13 ANSWER 1 OF 52 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 1  
AN 2002:249967 CAPLUS  
DN 136:278130  
TI Cellular immunogens comprising cognate proto-  
oncogenes for use in cancer vaccines  
IN Halpern, Michael S.; England, James M.  
PA Philadelphia Health and Educational Corporation, USA  
SO U.S., 35 pp., Cont.-in-part of U.S. Ser. No. 101,226, abandoned.  
DT Patent  
LA English  
FAN CNT 2

PATENT NO. KIND DATE APPLICATION NO. DATE  
-----  
PI US 6365151 B1 20020402 US 1998-167322 19981007  
WO 9725860 A1 19970724 WO 1997-US582 19970113  
W: AU, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,

DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LU, LS, LT, LV, LY, MD, MG, MK, MN, MM, NO, NZ, PL, PT,  
RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, AM,  
AZ, BY, KG, KD, MD, RU, TJ, TM  
RK: KE, LS, MM, SD, SZ, US, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR,  
IE, IT, LU, MC, NL, PT, SE, BF, BJ, CG, CI, CM, GA, GN, ML,  
MR, NE, SN, TD, TG  
PRAI US 1996-10262P P 19960119  
WO 1997-US582 A2 19970113  
US 1998-101226 B2 19980702  
RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 2 OF 52 USPTFULL  
AN 2002:166378 USPTFULL  
TI Minimal adenovirus mediated recombinant vaccine  
IN Fang, Xiangming, San Diego, CA, UNITED STATES  
Gallichan, Scott, San Diego, CA, UNITED STATES  
Zhang, Wei-Wei, San Diego, CA, UNITED STATES  
Wong-Straal, Flossie, San Diego, CA, UNITED STATES  
Sauter, Sybille, Del Mar, CA, UNITED STATES  
PI US 2002088014 A1 20020704  
US 2001-974206 A1 20010100 (9)  
RLI Continuation-in-part of Ser. No. US 1997-866403, filed on 30 May 1997,  
PENDING Continuation-in-part of Ser. No. US 1997-791218, filed on 31 Jan  
1997, ABANDONED Continuation-in-part of Ser. No. US 1996-658961, filed  
on 31 May 1996, PENDING  
PRAI US 2000-239224P 20001010 (60)  
US 2000-241625P 20001019 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 4062  
INCL INCLM: 800/008.000 435/456.000; 435/235.100  
INCL INCLM: 435/320.100; 435/456.000; 435/235.100  
NCL NCLM: 800/008.000  
NCLS: 435/320.100; 435/456.000; 435/235.100  
IC [7]  
ICM: A01K067-00  
ICS: C12N015-867; C12N015-861; C12N007-00; C12N007-01  
L13 ANSWER 3 OF 52 USPTFULL  
AN 2002:133493 USPTFULL  
TI 98P7C3: homodomain protein highly expressed in various cancers  
IN Hubert, Rene S., Los Angeles, CA, UNITED STATES  
Fairis, Mary, Los Angeles, CA, UNITED STATES  
Afari, Daniel E.H., Brisbane, CA, UNITED STATES  
Levin, Eliana, Los Angeles, CA, UNITED STATES  
Mitchell, Steve Chappell, Santa Monica, CA, UNITED STATES  
Jakobovits, Aya, Beverly Hills, CA, UNITED STATES  
PI US 2002068345 A1 20020606  
US 2001-866359 A1 20010524 (9)  
PRAI US 2000-207138P 20000524 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 6137  
INCL INCLM: 435/183.000  
INCL INCLM: 435/325.000; 435/320.100; 435/069.100  
NCL NCLM: 435/183.000  
NCLS: 435/325.000; 435/320.100; 435/069.100  
IC [7]  
ICM: C12P021-02  
ICS: C12N009-00; C12N005-06  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 4 OF 52 USPTFULL  
AN 2002:106269 USPTFULL  
TI GTP-binding protein useful in treatment and detection of cancer  
IN Fairis, Mary, Los Angeles, CA, UNITED STATES  
Challita-Eid, Pia M., Encino, CA, UNITED STATES  
Raitano, Arthur B., Los Angeles, CA, UNITED STATES  
Mitchell, Steve Chappell, Santa Monica, CA, UNITED STATES  
Afari, Daniel E.H., Brisbane, CA, UNITED STATES  
Jakobovits, Aya, Beverly Hills, CA, UNITED STATES  
PI US 2002055478 A1 20020509  
US 2001-834765 A1 20010412 (9)  
PRAI US 2000-19647P 20000412 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 5003  
INCL INCLM: 514/044.000  
INCL INCLM: 435/006.000; 435/007.230  
NCL NCLM: 514/044.000  
NCLS: 435/006.000; 435/007.230  
IC [7]  
ICM: A61K048-00  
ICS: C12O001-68; C01N033-574  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 5 OF 52 USPTFULL  
AN 2002:84909 USPTFULL  
TI Methods and compositions for co-stimulation of immunological responses  
IN Kleif, Samir, Silver Spring, MD, UNITED STATES  
Berzofsky, Jay, Bethesda, MD, UNITED STATES  
PI US 2002044948 A1 20020418  
US 2001-810310 A1 20010314 (9)  
PRAI US 2000-189396P 20000315 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 3104  
INCL INCLM: 424/234.100  
INCL INCLM: 424/184.100; 530/350.000  
NCL NCLM: 424/234.100  
NCLS: 424/184.100; 530/350.000  
IC [7]  
ICM: A61K039-00  
ICS: A61K039-38; A61K039-02; C07K001-00; C07K014-00; C07K017-00  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L13 ANSWER 6 OF 52 USPTFULL  
AN 2002:43212 USPTFULL  
TI Formulations for electroporation  
IN MacLaughlin, Fiona, Belfast, UNITED KINGDOM  
Li, Shulin, The Woodlands, TX, UNITED STATES  
Li, Yuhua, The Woodlands, TX, UNITED STATES  
Petrak, Karel, Spring, TX, UNITED STATES  
PA Valentis, Inc., The Woodlands, TX (non-U.S. corporation)  
PI US 2002025578 A1 20020228  
US 2001-903009 A1 20010710 (9)  
RLI Continuation of Ser. No. US 1999-322602, filed on 28 May 1999, PENDING  
PRAI US 1998-88691P 19980608 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 1353  
INCL INCLM: 435/463.000  
INCL INCLM: 435/463.000  
IC [7]

ICM: C12N015-87  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 7 OF 52 USPATFULL  
 AN 2002:16585 USPATFULL  
 TI Porcine neural cells and their use in treatment of neurological deficits  
 IN due to neurodegenerative diseases  
 PA Isaacson, Ole, Cambridge, MA, UNITED STATES  
 DIacrin, Inc. (U.S. corporation)  
 AI US 2002009461 A1 20020124  
 US 2001-847881 A1 20010502 (9)  
 RLI Division of Ser. No. US 1995-554779, filed on 7 Nov 1995, GRANTED. Pat.  
 No. US 6258353 Continuation-in-part of Ser. No. US 1995-424851, filed on  
 19 Apr 1995, GRANTED. Pat. No. US 6294383 Continuation-in-part of Ser.  
 No. US 1994-336856, filed on 8 Nov 1994, ABANDONED

DT UTILITY  
 PS APPLICATION  
 LN.CNT 5037  
 INCL INCLM: 424/193.100  
 INCLS: 424/093.700; 435/325.000  
 NCL NCLM: 424/193.100  
 NCLS: 424/093.700; 435/325.000  
 IC [7]  
 ICM: A61K039-385  
 ICS: C12N005-06; A61K045-00  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 8 OF 52 USPATFULL  
 AN 2002:144239 USPATFULL  
 TI Tumor antigens and CTL clones isolated by a novel procedure  
 IN Luftein, Rosalie, Brussels, BELGIUM  
 Dufleur, Marie-Therese, Brussels, BELGIUM  
 Demotte, Nathalie, Brussels, BELGIUM  
 van der Brugan, Pierre, Brussels, BELGIUM  
 Cornelius, Guy, Brussels, BELGIUM  
 Stroobant, Vincent, Brussels, BELGIUM  
 Lurquin, Christophe, Brussels, BELGIUM  
 Boon-Falleur, Thierry, Brussels, BELGIUM  
 Ludwig Institute for Cancer Research, New York, NY, United States (U.S.  
 corporation)  
 PA Universite Catholique de Louvain, Louvain-la-Neuve, BELGIUM (non-U.S.  
 corporation)  
 PI US 6407063 B1 20020618  
 AI US 1998-165863 19981002 (9)  
 DT UTILITY  
 PS GRANTED  
 LN.CNT 1456  
 INCL INCLM: 514/013.000  
 INCLS: 530/326.000; 530/328.000; 514/015.000  
 NCL NCLM: 514/013.000  
 NCLS: 530/326.000; 530/328.000; 514/015.000  
 IC [7]  
 ICM: A61K038-08  
 ICS: A61K038-10; C07K007-06; C07K007-08  
 514/15; 514/13; 530/328; 530/326  
 EXF INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 9 OF 52 USPATFULL  
 AN 2002:116068 USPATFULL  
 TI Recombinant alphavirus-based vectors with reduced inhibition of cellular  
 macromolecular synthesis  
 IN Dubensky, Jr., Thomas W., Del Mon, CA, United States  
 Polo, John W., Encinitas, CA, United States

PA Belli, Barbara A., San Diego, CA, United States  
 Schlesinger, Sondra, St. Louis, MO, United States  
 Dryga, Sergey A., Fort Collins, CO, United States  
 Frolov, Ilya, St. Louis, MO, United States  
 Chiron Corporation, Emeryville, CA, United States (U.S. corporation)  
 PI Washington University, St. Louis, MO, United States (U.S. corporation)  
 AI US 6391632 B1 20020521  
 US 1999-415784 19991008 (9)  
 RLI Division of Ser. No. US 1997-944465, filed on 6 Oct 1997  
 Continuation-in-part of Ser. No. US 1997-831148, filed on 4 Apr 1997,  
 now abandoned Continuation-in-part of Ser. No. US 1996-679640, filed on  
 12 Jul 1996, now abandoned Continuation-in-part of Ser. No. US  
 1996-668953, filed on 24 Jun 1996, now abandoned Continuation-in-part of  
 Ser. No. US 1996-628594, filed on 5 Apr 1996, now abandoned

DT UTILITY  
 PS GRANTED  
 LN.CNT 8166  
 INCL INCLM: 435/325.000  
 INCLS: 435/069.100; 435/457.000; 536/023.720  
 NCL NCLM: 435/325.000  
 NCLS: 435/069.100; 435/457.000; 536/023.720  
 IC [7]  
 ICM: C12N005-10  
 EXF 435/325; 435/69.1; 435/457; 536/23.72  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 10 OF 52 USPATFULL  
 AN 2002:19216 USPATFULL  
 TI Nucleotide and deduced amino acid sequences of tumor gene Int6  
 IN Marchetti, Antonio, Viareggio, ITALY  
 Buttila, Piamma, Viareggio, ITALY  
 Smith, Gilbert H., Falls Church, VA, United States  
 Callahan, Robert, Alexandria, VA, United States  
 The United States of America, as represented by the Department of Health  
 and Human Services, Washington, DC, United States (U.S. corporation)  
 PA US 6442392 B1 20020129  
 AI US 1999-378842 19990823 (9)  
 RLI Division of Ser. No. US 875847 Continuation-in-part of Ser. No. US  
 1995-385998, filed on 9 Feb 1995, now abandoned

DT UTILITY  
 PS GRANTED  
 LN.CNT 2076  
 INCL INCLM: 436/063.000  
 INCLS: 436/086.000; 435/006.000  
 NCL NCLM: 436/063.000  
 NCLS: 435/006.000; 436/086.000  
 IC [7]  
 ICM: G01N033-48  
 ICS: G01N033-00; C12Q001-68  
 514/12; 436/63; 436/86; 435/6  
 EXF INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 11 OF 52 USPATFULL  
 AN 2002:13790 USPATFULL  
 TI Superantigen based methods and compositions for treatment of diseases  
 IN Teman, David Stephen, 3183 Palmetto Way, Pebble Beach, CA, United States  
 PI US 6340461 B1 20020122  
 AI US 1997-992877 19971217 (8)  
 PRAI US 1996-33172P 19961217 (60)  
 US 1997-44074P 19970417 (60)  
 DT UTILITY  
 PS GRANTED  
 LN.CNT 5893

INCL INCLM: 424/193.100  
 INCLS: 424/192.100; 424/194.100; 424/277.100; 424/278.100; 424/280.100;  
 424/282.100; 435/068.100; 435/069.100; 435/069.300; 435/069.700  
 NCL NCLM: 424/193.100  
 NCLS: 424/192.100; 424/194.100; 424/277.100; 424/278.100; 424/280.100;  
 424/282.100; 435/068.100; 435/069.100; 435/069.300; 435/069.700  
 IC [7]  
 ICM: A61K039-385  
 ICS: A61K039-00; A61K039-39; A61K045-00; C12N015-09; C12N015-12;  
 C12N015-62; C12N015-63  
 EXP 424/277.1; 424/193.1; 424/194.1; 424/192.1; 424/278.1; 424/280.1;  
 424/282.1; 435/68.1; 435/69.7; 435/69.3; 435/69.1  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L13 ANSWER 12 OF 52 USPATFULT  
 AN 2002:9741 USPATFULT  
 TI Method for identifying cytotoxic T-cell epitopes  
 IN Nicolette, Charles A., Marlborough, MA, United States  
 PA Genzyme Corporation, Framingham, MA, United States (U.S. corporation)  
 PI US 6338945 B1 20020115  
 P1 US 1997-989195 19971211 (8)  
 RLI Continuation of Ser. No. MO 1997-US4479, filed on 20 Mar 1997  
 PRAI US 1996-13706P 19960320 (60)  
 DT Utility  
 FS GRANTED  
 LN CNT 1648  
 INCL INCLM: 435/007.100  
 INCLS: 435/004.000; 435/DIG.001; 435/DIG.015; 435/DIG.035; 530/300.000;  
 530/328.000; 436/518.000  
 NCL NCLM: 435/007.100  
 NCLS: 435/004.000; 435/DIG.001; 435/DIG.015; 435/DIG.035; 436/518.000;  
 530/300.000; 530/328.000  
 IC [7]  
 ICM: G01N033-53  
 ICS: G01N033-543; A61K038-00  
 EXP 530/300; 530/327; 530/328; 530/333; 530/334; 530/335; 436/518; 436/501;  
 436/524; 435/77.1; 435/DIG.1; 435/DIG.2; 435/DIG.14; 435/DIG.15;  
 435/DIG.22; 435/DIG.34; 435/DIG.35; 435/DIG.21  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L13 ANSWER 13 OF 52 USPATFULT  
 AN 2001:212422 USPATFULT  
 TI Treatment of allergies  
 IN Levy, Shoshana, Stanford, CA, United States  
 Dekruyff, Rosemarie H., Stanford, CA, United States  
 Umersu, Haiden, Mountain View, CA, United States  
 PI US 2001044418 A1 20011122  
 P1 US 2001-798075 A1 20010302 (9)  
 PRAI US 2000-188311P 20000310 (60)  
 DT Utility  
 FS APPLICATION  
 LN CNT 1218  
 INCL INCLM: 514/044.000  
 INCLS: 424/085.200  
 NCL NCLM: 514/044.000  
 NCLS: 424/085.200  
 IC [7]  
 ICM: A61K048-00  
 ICS: A61K038-20  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L13 ANSWER 14 OF 52 USPATFULT  
 AN 2001:199741 USPATFULT

TI Cancer immunotherapy using autologous tumor cells combined with cells  
 expressing a membrane cytokine  
 IN Hiserodt, John C., Huntington Beach, CA, United States  
 Graf, Martin R., Richmond VA, United States  
 PI US 2001038841 A1 20011108  
 P1 US 2001-875349 A1 20010605 (9)  
 RLI Division of Ser. No. US 1997-901225, filed on 24 Jul 1997, GRANTED, Pat.  
 PRAI No. US 6277368  
 US 1996-23108P 19960725 (60)  
 DT US 1996-29286P 19961029 (60)  
 FS Utility  
 LN CNT 2638  
 INCL INCLM: 424/130.100  
 INCLS: 424/277.100; 435/368.000  
 NCL NCLM: 424/130.100  
 NCLS: 424/277.100; 435/368.000  
 IC [7]  
 ICM: A61K039-395  
 ICS: A61K039-00; C12N005-08  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L13 ANSWER 15 OF 52 USPATFULT  
 AN 2001:193945 USPATFULT  
 TI Cancer immunotherapy using autologous tumor cells combined with cells  
 expressing a membrane cytokine  
 IN Hiserodt, John C., Huntington Beach, CA, United States  
 Graf, Martin R., Richmond, VA, United States  
 PI US 2001036458 A1 20011101  
 P1 US 2001-875823 A1 20010605 (9)  
 RLI Division of Ser. No. US 1997-901225, filed on 24 Jul 1997, GRANTED, Pat.  
 PRAI No. US 6276923  
 US 1996-23108P 19960725 (60)  
 DT US 1996-29286P 19961029 (60)  
 FS Utility  
 LN CNT 2634  
 INCL INCLM: 424/130.100  
 INCLS: 424/277.100; 435/368.000  
 NCL NCLM: 424/130.100  
 NCLS: 424/277.100; 435/368.000  
 IC [7]  
 ICM: A61K039-395  
 ICS: A61K039-00; C12N005-08  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L13 ANSWER 16 OF 52 USPATFULT  
 AN 2001:167936 USPATFULT  
 TI Hepatitis therapeutics  
 IN Jolly, Douglas J., Leucadia, CA, United States  
 Chang, Stephen M. W., Poway, CA, United States  
 Lee, William T. L., Carlsbad, CA, United States  
 Townsend, Kay, Encinitas, CA, United States  
 O'Dea, Joanne, La Jolla, CA, United States  
 PA Chiron Corporation, Emeryville, CA, United States (U.S. corporation)  
 PI US 6297048 19950607 (8)  
 P1 US 1995-483511 19950607 (8)  
 RLI Continuation-in-part of Ser. No. US 1995-374414, filed on 19 Jan 1995,  
 now abandoned Continuation-in-part of Ser. No. US 1994-286829, filed on  
 5 Aug 1994, now abandoned Continuation-in-part of Ser. No. US  
 1993-102132, filed on 4 Aug 1993, now abandoned Continuation-in-part of  
 Ser. No. US 1993-32385, filed on 17 Mar 1993, now abandoned

Continuation-in-part of Ser. No. US 1992-830417, filed on 4 Feb 1992, now abandoned

DT Utility  
 FS GRANTED  
 LN.CNT 3732  
 INCL INCLM: 435/320.100  
 INCLM: 435/320.100  
 NCLM: 435/069.300  
 NCL NCLM: 435/320.100  
 NCLM: 435/069.300  
 IC [7]  
 ICM: C12N015-63  
 ICS: C12P021-02  
 EXF 435/69.1; 435/69.3; 435/320.1; 424/228.1  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 17 OF 52 USPTAFULL  
 AN 2001:136177 USPTAFULL  
 TI Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine  
 IN Hiseodt, John C., Huntington Beach, CA, United States  
 Graf, Martin R., Richmond, VA, United States  
 Grainger, Gale A., Laguna Beach, CA, United States  
 PA The Regents of the University of California, Oakland, CA, United States (U.S. corporation)  
 PI US 6277368 B1 20010821  
 AI US 1997-801225 19970724 (8)  
 PRAI US 1996-23108P 19960725 (60)  
 DT US 1996-29286P 19961029 (60)  
 FS Utility  
 INCL GRANTED  
 LN.CNT 2892  
 INCLM: 424/093.210  
 INCLM: 424/093.100; 424/093.300; 424/093.710; 424/085.100;  
 NCLM: 424/085.200; 424/085.600; 424/277.100; 435/325.000  
 NCL NCLM: 424/093.210  
 NCLM: 424/085.100; 424/085.200; 424/085.600; 424/093.100; 424/093.300;  
 IC [7]  
 ICM: A01N063-00  
 ICS: C12N015-85; A61K035-12; A61K035-19  
 EXF 424/93.21; 424/93.1; 424/93.3; 424/93.7; 424/93.71; 424/85.1; 424/85.2;  
 424/85.4; 424/277.1; 435/325  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 18 OF 52 USPTAFULL  
 AN 2001:107439 USPTAFULL  
 TI Porcine neural cells and their use in treatment of neurological deficits due to neurodegenerative diseases  
 IN Isaacson, Ole, Cambridge, MA, United States  
 PA Diacrin, Jonathan, Brookline, MA, United States  
 PI Diacrin, Inc., Charlestown, MA, United States (U.S. corporation)  
 AI US 6258353 B1 20010710  
 US 1995-554779 19951107 (8)  
 RLI Continuation-in-part of Ser. No. US 1995-424851, filed on 19 Apr 1995, now abandoned  
 DT Utility  
 FS GRANTED  
 LN.CNT 5157  
 INCL INCLM: 424/093.100  
 INCLM: 424/093.700; 424/130.100; 424/143.100; 424/809.000; 435/325.000;  
 NCLM: 435/368.000  
 NCLM: 424/093.100  
 NCLM: 424/093.700; 424/130.100; 424/143.100; 424/809.000; 435/325.000;

IC [7]  
 ICM: A01N003-00  
 ICS: C12N015-85; C12N015-86; A61K039-395  
 EXF 424/93.7; 424/93.1; 424/130.1; 424/143.1; 424/809.000; 435/325.000  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 19 OF 52 USPTAFULL  
 AN 2001:102615 USPTAFULL  
 TI Nucleotide and deduced amino acid sequences of tumor gene int6  
 IN Marchetti, Antonio, Viareggio, Italy  
 Butticci, Fiama, Viareggio, Italy  
 Smith, Gilbert H., Falls Church, VA, United States  
 Callahan, Robert, Alexandria, VA, United States  
 PA The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)  
 PI US 6255105 B1 20010703  
 AI WO 9624672 19970815  
 US 1997-875847 19970925 (8)  
 WO 1996-US1884 19960209  
 DT US 1997-875847 19970925 PCT 371 date  
 RLI Continuation-in-part of Ser. No. US 1995-385998, filed on 9 Feb 1995, now abandoned  
 DT Utility  
 FS GRANTED  
 LN.CNT 1789  
 INCL INCLM: 435/325.000  
 INCLM: 435/320.100; 435/069.100  
 NCLM: 435/252.300; 435/325.000  
 NCL NCLM: 435/069.100; 435/252.300; 435/320.100  
 IC [7]  
 ICM: C12N005-00  
 ICS: C12N015-00; C12N001-20; C12P021-06  
 EXF 435/69.1; 435/320.1; 435/325.000; 435/252.3; 435/366; 435/371; 435/252.8  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 20 OF 52 USPTAFULL  
 AN 2001:67168 USPTAFULL  
 TI Cancer therapy using an oncogene product and a foreign MHC molecule  
 IN Maudeley, David John, 18 Common Lane, Kenilworth, Warwickshire CV8 2ER, United Kingdom  
 PI US 6228357 B1 20010508  
 AI WO 9814205 19980409  
 US 1999-269686 19990330 (9)  
 WO 1997-GB2691 19990330 PCT 371 date  
 PRAI GB 1996-20350 19960930 PCT 102(e) date  
 DT Utility  
 FS GRANTED  
 LN.CNT 330  
 INCL INCLM: 424/093.200  
 INCLM: 424/093.100; 424/093.210; 424/325.000  
 NCLM: 424/093.200  
 NCL NCLM: 424/093.100; 424/093.210; 435/325.000  
 IC [7]  
 ICM: C12N015-85  
 ICS: C12N015-80  
 EXF 424/93.1; 424/325; 424/93.2; 424/93.21  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 21 OF 52 USPTAFULL

AN 2001:55742 USPATFULTL  
 TI Adjuvant incorporation into antigen carrying cells: compositions and  
 methods  
 IN Ravindranath, Mepur H., Los Angeles, CA, United States  
 PA Morron, Donald L., Malibu, CA, United States  
 John Wayne Cancer Institute, Santa Monica, CA, United States (U.S.  
 corporation)  
 PI US 6218166 B1 20010417  
 AI US 1995-462106 19950605 (8)  
 RLI Continuation-in-part of Ser. No. US 1994-353549, filed on 9 Dec 1994,  
 now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 5039  
 INCL INCLM: 435/240.100; 424/277.100; 424/283.100; 424/184.100; 424/078.310;  
 INCLS: 424/278.100; 424/179.100; 424/174.100; 424/150.100; 424/201.100  
 NCLM: 435/366.000  
 NCLS: 424/078.310; 424/150.100; 424/174.100; 424/179.100; 424/184.100;  
 424/201.100; 424/240.100; 424/277.100; 424/278.100; 424/283.100;  
 435/325.000; 435/354.000; 435/372.000  
 IC [7]  
 ICM: A61K039-00  
 ICS: A61K045-00; A61K039-40; A61K039-395  
 EXF 424/240.1; 424/277.1; 424/283.1; 424/184.1; 424/78.31; 424/278.1;  
 424/179.1; 424/150.1; 424/201.1; 424/174.1; 435/240.2  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 22 OF 52 USPATFULTL  
 AN 2001:33252 USPATFULTL  
 TI Compositions and methods for delivery of genetic material  
 IN Carrano, Richard A., Paoli, PA, United States  
 Wang, Bin, Haidian, China  
 Weiher, David B., Merion, PA, United States  
 The Trustees of the University of Pennsylvania, Philadelphia, PA, United  
 States (U.S. corporation)  
 PA Apollan, Inc., Malvern, PA, United States (U.S. corporation)  
 PI US 6197755 B1 20010306 (9)  
 AI US 1999-321461 19990527 (9)  
 RLI Continuation of Ser. No. US 704701, now patented, Pat. No. US 5962428  
 Continuation of Ser. No. US 1994-221579, filed on 1 Apr 1994, now  
 patented, Pat. No. US 5739118, issued on 14 Apr 1998  
 DT Utility  
 FS Granted  
 LN.CNT 3329  
 INCL INCLM: 514/044.000  
 INCLS: 424/278.100  
 NCLM: 514/044.000  
 NCLS: 424/278.100  
 IC [7]  
 ICM: A61K031-7088  
 ICS: A61K045-05  
 EXF 424/93.1; 424/278.1; 435/69.1; 435/320.1; 514/44  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 23 OF 52 USPATFULTL  
 AN 2001:21755 USPATFULTL  
 TI Cancer immunotherapy with semi-allogeneic cells  
 IN Cohen, Edward F., Chicago, IL, United States  
 PA Research Corporation Technologies, Inc., Tucson, AZ, United States (U.S.  
 corporation)  
 PI US 6187307 B1 20010213  
 AI US 1998-16528 19980130 (9)  
 PRAI US 1997-36620P 19970131 (60)

DT Utility  
 FS Granted  
 LN.CNT 2184  
 INCL INCLM: 424/093.210  
 INCLS: 424/093.710; 435/455.000; 435/372.000; 435/366.000; 435/325.000;  
 536/023.500  
 NCLM: 424/093.210  
 NCLS: 424/093.710; 435/325.000; 435/366.000; 435/372.000; 435/455.000;  
 536/023.500  
 IC [7]  
 ICM: C12N005-10  
 ICS: C12N005-08; A01N063-00  
 EXF 435/325; 435/455; 435/366; 435/372; 424/93.21; 424/93.71; 536/23.5  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 24 OF 52 CAPLUS COPYRIGHT 2002 ACS  
 AN 2000:84650 CAPLUS  
 DN 132:136415  
 TI Allogeneic cellular immunogens useful as cancer  
 vaccines  
 IN Halpern, Michael S.; England, James M.  
 PA Allegheny University of the Health Sciences, USA  
 SO PCT Int. Appl. 77 pp.  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 200004927	A1	20000203	WO 1999-US15594	19990708
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, GR, GU, HD, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LU, LV, MD, MG, MK, MW, MX, MY, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UC, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, CZ, DE, CH, GM, KE, US, MW, SD, SL, SZ, UC, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	<p>AU 9949819 A1 20000214 19990708</p> <p>EP 1100544 A1 20010523 19990708</p> <p>R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO</p>			
PRAI US 1998-93965P	P	19980724		
WO 1999-US15594	M	19990708		
RE.CNT 1				

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 25 OF 52 USPATFULTL  
 AN 2000:146162 USPATFULTL  
 TI Isolated and modified porcine cerebral cortical cells  
 IN Dinmore, Jonathan, Brookline, MA, United States  
 PA Diacrin, Inc., Charlestown, MA, United States (U.S. corporation)  
 PI US 6140116 20001031 (8)  
 AI US 1995-551820 19951107 (8)  
 RLI Continuation-in-part of Ser. No. US 1995-424856, filed on 19 Apr 1995  
 which is a continuation-in-part of Ser. No. US 1995-336856, filed on 8  
 Nov 1995, now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 5001  
 INCL INCLM: 435/325.000  
 INCLS: 435/374.000; 424/093.700  
 NCLM: 435/325.000

NCLs: 424/093.700; 435/374.000  
 IC (7)  
 ICM: C12N005-00  
 EXP 435/325; 435/374; 435/93.7  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L13 ANSWER 26 OF 52 USPTAFULL  
 AN 2000:117521 USPTAFULL  
 TI DNA encoding density enhanced protein tyrosine phosphatases  
 IN Tonks, Nicholas K., Huntington, NY, United States  
 PA Ostman, Arne, Uppsala, Sweden  
 PA Cold Spring Harbor Laboratory, United States (U.S. corporation)  
 PI US 6114140 20000905  
 AI US 1997-854585 19970512 (8)  
 RLI Continuation of Ser. No. US 1994-237940, filed on 3 May 1994, now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 1539  
 INCL INCLM: 435/069.100  
 INCLS: 435/196.000; 435/325.000; 435/252.300; 435/254.110; 435/320.100;  
 435/471.000; 536/023.500; 536/024.300; 536/024.310; 530/350.000  
 NCLM: 435/069.100  
 NCLS: 435/196.000; 435/252.300; 435/254.110; 435/320.100; 435/325.000;  
 435/471.000; 530/350.000; 536/023.500; 536/024.300; 536/024.310  
 IC (7)  
 ICM: C12N015-52  
 ICS: C12N015-63; C12N005-10  
 EXP 435/69.1; 435/196; 435/325; 435/252.3; 435/254.11; 435/320.1; 435/471;  
 536/23.5; 536/24.3; 536/24.11; 530/350  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L13 ANSWER 27 OF 52 USPTAFULL  
 AN 2000:109594 USPTAFULL  
 TI XAF genes and polypeptides: methods and reagents for modulating  
 IN apoptosis  
 IN Korneluk, Robert G., Ottawa, Canada  
 PA Tamai, Katsuyuki, Nagano, Japan  
 PA Liston, Peter, Ottawa, Canada  
 PA MacKenzie, Alexander E., Ottawa, Canada  
 PA Apoptogen Inc., Ottawa, (non-U.S. corporation)  
 PI US 6107088 20000822  
 AI US 1998-100391 19980619 (9)  
 PRAI US 1997-52402P 19970714 (60)  
 US 1997-54481P 19970801 (60)  
 US 1997-56338P 19970818 (60)  
 DT Utility  
 FS Granted  
 LN.CNT 4426  
 INCL INCLM: 435/325.000  
 INCLS: 536/023.100; 536/023.500; 536/024.100; 536/024.500; 435/320.100;  
 435/375.000; 435/377.000  
 NCLM: 435/325.000  
 NCLS: 435/320.100; 435/375.000; 435/377.000; 536/023.100; 536/023.500;  
 536/024.100; 536/024.500  
 IC (7)  
 ICM: C12N015-85  
 ICS: C12N015-63; C07H021-04  
 EXP 435/325; 435/243; 435/410; 435/69.1; 435/69.2; 435/320.1; 435/353;  
 435/363; 435/375; 435/377; 536/23.1; 536/23.5; 536/24.5; 536/24.1  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L13 ANSWER 28 OF 52 USPTAFULL  
 AN 2000:70820 USPTAFULL

TI Insulin-like growth factor 1 receptors (IGF-IR) antisense  
 IN oligonucleotide cell composition  
 IN Low, Walter C., Shorewood, MN, United States  
 PA Mallenfriedman, Margaret A., Edina, MN, United States  
 PA Chiang, Ian, Plymouth, MN, United States  
 PA Regents of the University of Minnesota, Minneapolis, MN, United States  
 PI US 6071891 20000606  
 AI US 1996-755558 19961122 (8)  
 DT Utility  
 FS Granted  
 LN.CNT 999  
 INCL INCLM: 514/044.000  
 INCLS: 424/277.100; 435/006.000; 435/320.100; 435/325.000; 435/353.000;  
 514/044.000; 536/023.100; 536/024.310; 536/024.500  
 NCLM: 514/044.000  
 NCLS: 424/277.100; 435/006.000; 435/320.100; 435/325.000; 435/353.000;  
 536/023.100; 536/024.310; 536/024.500  
 IC (7)  
 ICM: A61K048-00  
 ICS: A61K035-12; C12N015-85; C07H021-04  
 EXP 435/6; 435/91.1; 435/172.1; 435/440; 435/320.1; 435/353; 435/325;  
 536/23.1; 536/24.31; 536/24.5; 514/44; 424/274.1  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L13 ANSWER 29 OF 52 USPTAFULL  
 AN 2000:61176 USPTAFULL  
 TI Method for determining oncogenic activity of a substance  
 IN Schreiber, Robert, St. Louis, MO, United States  
 PA Old, Lloyd J., New York, NY, United States  
 PA Washington University, St. Louis, MO, United States (U.S. corporation)  
 PI US 6063359 20000516  
 AI US 1997-938295 19970926 (8)  
 DT Utility  
 FS Granted  
 LN.CNT 1072  
 INCL INCLM: 424/009.200  
 INCLS: 424/009.100; 424/277.100; 424/093.100; 800/003.000; 800/008.000;  
 800/018.000; 800/014.000  
 NCLM: 424/009.200  
 NCLS: 424/009.100; 424/093.100; 424/277.100; 800/003.000; 800/008.000;  
 800/014.000; 800/018.000  
 IC (7)  
 ICM: C12N005-00  
 ICS: A61K049-00  
 EXP 800/3; 800/8; 800/18; 800/14; 424/93.1; 424/93.21; 424/277.1; 424/9.1;  
 424/9.2  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L13 ANSWER 30 OF 52 USPTAFULL  
 AN 2000:1745 USPTAFULL  
 TI Antibody heteroconjugates and bispecific antibodies for use in  
 IN regulation of lymphocyte activity  
 IN Isabetter, Jeffrey A., Seattle, WA, United States  
 PA Gilliland, Lisa K., Seattle, WA, United States  
 PA Bristol-Meyers Squibb Company, Princeton, NJ, United States (U.S. corporation)  
 PI US 6010902 20000104  
 AI US 1994-366401 19941229 (8)  
 PRAI US 1994-366401 19941229 (8)  
 Continuation of Ser. No. US 1993-28527, filed on 9 Mar 1993, now  
 Abandoned which is a continuation of Ser. No. US 1992-880307, filed on 5  
 May 1992, now abandoned which is a continuation of Ser. No. US  
 1991-733369, filed on 19 Jul 1991, now abandoned which is a continuation  
 of Ser. No. US 1989-424801, filed on 20 Oct 1989, now abandoned which is

a continuation-in-part of Ser. No. US 1988-271934, filed on 14 Nov 1988, now abandoned which is a continuation-in-part of Ser. No. US 1988-176825, filed on 4 Apr 1988, now abandoned

DT Utility  
 FS Granted  
 LN CNT 2714  
 INCL INCLM: 435/328.000  
 INCLM: 435/332.000; 435/334.000; 530/388.750; 530/391.100; 530/405.000;  
 NCLM: 435/328.000  
 NCLM: 435/328.000  
 NCLM: 435/332.000; 435/334.000; 530/387.300; 530/388.750; 530/391.100;  
 NCLM: 530/405.000  
 IC [6]  
 ICM: C12N005-00  
 EXF ICS: C12N005-02; C07K016-00; C12P021-08  
 424/144.1; 424/179.1; 435/240.27; 435/328; 435/332; 435/334; 530/388.75;  
 530/391.1; 530/405; 530/387.3  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 31 OF 52 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B. V.  
 AN 2001096343 EMBASE  
 TI Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine.  
 AU Dakapagari N.K.; Douglas D.B.; Trilozzi P.L.; Stevens V.C.; Kamaya P.T.P.  
 CS P.T.P. Kamaya, Ohio State University, Comprehensive Cancer Center, 410 West 12th Avenue, Columbus, OH 43210, United States. Kamaya.1@osu.edu  
 SO Cancer Research, (15 Jul 2000) 60/14 (3782-3789).  
 Refs: 63  
 ISSN: 0008-5472 CODEN: CNRBA8  
 CY United States  
 DT Journal: Article  
 FS 016 Cancer  
 026 Immunology, Serology and Transplantation  
 037 Drug Literature Index  
 LA English  
 SL English

L13 ANSWER 32 OF 52 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B. V.  
 AN 2000418226 EMBASE  
 TI Differential expression of intracisternal A-particle transcripts in immunogenic versus tumorigenic S49 murine lymphoma cells.  
 AU Braun E.; Rorman E.; Lueders K.K.; Bar-Sinai A.; Hochman J.  
 CS J. Hochman, Dept. of Cell and Animal Biology, Hebrew University of Jerusalem, Jerusalem 91904, Israel. hochman@ms.huji.ac.il  
 SO Virology, (10 Nov 2000) 277/1 (136-146).  
 Refs: 40  
 ISSN: 0042-6822 CODEN: VIRLAX  
 CY United States  
 DT Journal: Article  
 FS 026 Immunology, Serology and Transplantation  
 LA English  
 SL English

L13 ANSWER 33 OF 52 USPTFULL  
 AN 1999-141912 USPTFULL  
 TI Compositions and methods for delivery of genetic material  
 IN Weiner, David B.; Merion, PA, United States  
 WI Williams, William V.; Havertown, PA, United States  
 PA The Trustees of The University of Pennsylvania, Philadelphia, PA, United States (U.S. corporation)  
 PI The Wistar Institute, Philadelphia, PA, United States (U.S. corporation)  
 US 5981505 19991109  
 WO 9416737 19940804

AI US 1997-979385 19971126 (8)  
 WO 1994-US899 19940126  
 19950828 PCT 371 date  
 19950828 PCT 102(e) date

RLI Continuation-in-part of Ser. No. US 1993-124962, filed on 21 Sep 1993, now abandoned And a continuation-in-part of Ser. No. US 1993-91335, filed on 15 Jul 1993, now abandoned And a continuation of Ser. No. US 1993-495684, filed on 28 Aug 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-125012, filed on 21 Sep 1993, now patented. Pat. No. US 5593972, issued on 14 Jan 1997 which is a continuation-in-part of Ser. No. US 1993-29336, filed on 11 Mar 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-8342, filed on 26 Jan 1993, now abandoned

DT Utility  
 FS Granted  
 LN CNT 4084  
 INCL INCLM: 514/044.000  
 INCLM: 514/044.000  
 NCLM: 514/044.000  
 NCLM: 514/044.000  
 NCLM: 514/044.000  
 NCLM: 514/044.000  
 IC [6]  
 ICM: A61K045-05  
 EXF ICS: A61K045-00; A61K031-00  
 514/44; 514/615; 514/818; 435/320.1; 435/93.1; 435/93.2; 435/93.21;  
 435/975; 424/278.1  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 34 OF 52 USPTFULL  
 AN 1999-141300 USPTFULL  
 TI Agonist murine monoclonal antibody as a stimulant for megakaryocytopoiesis  
 IN Avraham, Hava; Brookline, MA, United States  
 PA Groopman, Jerome E.; Brookline, MA, United States  
 (U.S. corporation)  
 PI US 5980893 19991109  
 AI US 1997-895626 19970717 (8)  
 DT Utility  
 FS Granted  
 LN CNT 969  
 INCL INCLM: 424/144.100  
 INCLM: 424/133.100; 424/135.100; 424/142.100; 424/143.100; 424/153.100;  
 INCLM: 424/178.100; 424/093.700; 435/076.210; 435/334.000; 435/343.000;  
 NCLM: 530/387.300; 530/388.150; 530/388.200; 530/388.220; 530/388.700;  
 NCLM: 530/389.600; 530/391.100  
 NCLM: 424/093.700; 424/133.100; 424/135.100; 424/142.100; 424/143.100;  
 NCLM: 424/153.100; 424/178.100; 435/076.210; 435/334.000; 435/343.000;  
 NCLM: 530/387.300; 530/388.150; 530/388.200; 530/388.220; 530/388.700;  
 NCLM: 530/389.600; 530/391.100  
 IC [6]  
 ICM: C07K016-28  
 EXF ICS: C12N005-12  
 424/93.7; 424/133.1; 424/135.1; 424/142.1; 424/143.1; 424/144.1;  
 424/153.1; 424/178.1; 435/70.21; 435/334; 435/343; 530/387.3;  
 530/388.15; 530/388.2; 530/388.22; 530/388.7; 530/389.6; 530/391.1  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 35 OF 52 USPTFULL  
 AN 1999-121330 USPTFULL  
 TI Compositions and methods for delivery of genetic material  
 IN Carrino, Richard A.; Paoli, PA, United States  
 WI Wang, Bin; Haidian, China  
 PI Weiner, David B.; Merion, PA, United States



PA Apollon, Inc., Malvern, PA, United States (U.S. corporation)  
The Trustees of The University of Pennsylvania, Philadelphia, PA, United States (U.S. corporation)  
PI US 5964248 19991005  
MO 9526718 19951012  
US 1996-704701  
MO 1995-US4071  
AI 19960916 (8)  
19950330  
19960916 PCT 371 date  
19960916 PCT 102(e) date

RLI Continuation of Ser. No. US 221579  
DT Utility  
FS Granted  
LN.CNT 3606  
INCL INCLM: 514/044.000  
NCL INCLM: 424/278.100  
NCLM: 514/044.000  
NCLM: 424/278.100  
IC [6]  
ICM: A61K031-70  
ICS: A61K045-05  
EXF 424/93.1; 424/278.1; 435/69.1; 435/172.3; 435/320.1; 514/44  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 36 OF 52 USPTAFULL  
AN 1999:106325 USPTAFULL  
TI Nucleic acids encoding antigen-binding sites specific for cancer antigens  
IN King, David B., Palo Alto, CA, United States  
PA Chiron Corporation, Emeryville, CA, United States (U.S. corporation)  
PI US 5948647 19990907  
US 1995-484508 19950607 (8)  
AI Continuation-in-part of Ser. No. US 1994-323566, filed on 17 Oct 1994, now abandoned which is a continuation of Ser. No. US 1993-11375, filed on 22 Oct 1993, now abandoned which is a continuation of Ser. No. US 1990-605399, filed on 29 Oct 1990, now abandoned  
DT Utility  
FS Granted  
LN.CNT 2409  
INCL INCLM: 435/069.600  
INCLM: 536/023.530; 435/070.210; 435/455.000; 435/328.000; 435/326.000; 435/330.000; 435/344.000; 435/346.000; 435/320.100; 530/387.700; 530/388.800; 530/389.700; 424/133.100; 424/138.100; 424/155.100; 424/174.100  
NCLM: 435/069.600  
NCLM: 424/133.100; 424/138.100; 424/155.100; 424/174.100; 435/320.100; 435/326.000; 435/328.000; 435/330.000; 435/344.000; 435/346.000; 435/455.000; 530/387.700; 530/388.800; 530/389.700; 536/023.530  
IC [6]  
ICM: C12N015-06  
ICS: C12N015-13; A61K039-395  
EXF 424/136.1; 424/143.1; 424/138.1; 424/85.1; 424/93.7; 424/133.1; 424/155.1; 424/174.1; 536/23.53; 435/69.6; 435/252.3; 435/240.22; 435/70.21; 435/455.000; 435/328.000; 435/326.000; 435/330.000; 435/344.000; 435/346.000; 530/387.700; 530/388.800; 530/389.700  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 37 OF 52 USPTAFULL  
AN 1998:157476 USPTAFULL  
TI Antigen-binding sites of antibody molecules specific for cancer antigens  
IN King, David B., Palo Alto, CA, United States  
PA Chiron Corporation, Emeryville, CA, United States (U.S. corporation)  
PI US 5849877 19981215  
US 1995-483199 19950607 (8)

RLI Continuation-in-part of Ser. No. US 1994-323566, filed on 17 Oct 1994, now abandoned which is a continuation of Ser. No. US 1993-141375, filed on 22 Oct 1993, now abandoned which is a continuation of Ser. No. US 1990-605399, filed on 29 Oct 1990, now abandoned  
DT Utility  
FS Granted  
LN.CNT 2276  
INCL INCLM: 530/387.100  
NCL INCLM: 530/387.300; 530/387.700; 530/388.100; 530/388.200; 530/388.800; 435/069.700; 435/070.210; 435/172.100; 435/326.000  
NCLM: 530/387.100  
NCLM: 435/069.700; 435/070.210; 435/326.000; 530/387.300; 530/387.700; 530/388.100; 530/388.200; 530/388.800  
IC [6]  
ICM: C07K016-00  
ICS: C12N005-00; C12N015-00; C12P021-04  
EXF 530/387.1; 530/387.3; 530/387.7; 530/388.1; 530/388.2; 530/388.8; 435/69.7; 435/70.21; 435/172.1; 435/326  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 38 OF 52 USPTAFULL  
AN 1998:135023 USPTAFULL  
TI Genetic immunization  
IN Weiner, David B., Merion, PA, United States  
PA Williams, William V., Havertown, PA, United States  
The Trustees of the University of Pennsylvania, Philadelphia, PA, United States (U.S. corporation)  
PI US 5830876 19981103  
US 1995-453349 19950530 (8)  
AI Continuation of Ser. No. US 1993-29336, filed on 11 Mar 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-8342, filed on 26 Jan 1993, now abandoned  
DT Utility  
FS Granted  
LN.CNT 2955  
INCL INCLM: 514/044.000  
INCLM: 424/278.100; 514/615.000; 514/818.000  
NCLM: 514/044.000  
NCLM: 424/278.100; 514/615.000; 514/818.000  
IC [6]  
ICM: A61K045-05  
ICS: A61K048-00; A61K031-00  
EXF 435/320.1; 424/93.1; 424/93.2; 424/93.21; 424/278.1; 514/44; 514/615; 514/818  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 39 OF 52 USPTAFULL  
AN 1998:122388 USPTAFULL  
TI Genetic immunization  
IN Weiner, David B., Merion, PA, United States  
PA Williams, William V., Havertown, PA, United States  
The Trustees of the University of Pennsylvania, Philadelphia, PA, United States (U.S. corporation)  
PI US 5817637 19981006  
US 1997-763818 19970113 (8)  
US 1997-763818 19981006  
AI Continuation of Ser. No. US 1993-125012, filed on 21 Sep 1993, now patented, Pat. No. US 5993972, issued on 14 Jan 1997 which is a continuation-in-part of Ser. No. US 1993-29336, filed on 11 Mar 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-8342, filed on 26 Jan 1993, now abandoned

DT Utility  
 FS Granted  
 LN.CNT 3641  
 INCL INCLM: 514/044.000  
 INCLS: 424/278.100; 435/975.000; 514/044.000; 514/615.000; 514/818.000  
 NCL NCLM: 514/044.000  
 NCLS: 424/278.100; 435/975.000; 514/615.000; 514/818.000  
 IC [6]  
 ICM: A61K045-05  
 ICS: A61K048-00; A61K031-00  
 EXP 514/44; 514/615; 514/818; 424/278.1; 435/975  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 40 OF 52 USPTFULT  
 AN 1998:115563 USPTFULT  
 TI Isolated nucleic acid molecules encoding antigen binding sites of  
 IN antibody molecules specific for cancer antigens  
 PA King, David B.; Palo Alto, CA, United States  
 PI Chilton Corporation, Emeryville, CA, United States (U.S. corporation)  
 PI US 5811267 19980922  
 RI US 1995-475600 19950607 (8)  
 RLI Continuation-in-part of Ser. No. US 1994-323566, filed on 17 Oct 1994,  
 now abandoned which is a continuation of Ser. No. US 1993-141375, filed  
 on 22 Oct 1993, now abandoned which is a continuation of Ser. No. US  
 1990-605399, filed on 29 Oct 1990, now abandoned

DT Utility  
 FS Granted  
 LN.CNT 2280  
 INCL INCLM: 435/069.700  
 INCLS: 435/070.210; 435/172.100; 435/172.300; 536/023.100; 536/023.400;  
 530/387.100; 530/387.300; 530/287.700; 530/388.800; 530/388.850  
 NCL NCLM: 435/069.700  
 NCLS: 435/070.210; 530/387.100; 530/387.300; 530/387.700; 530/388.800;  
 530/388.850; 536/023.100; 536/023.400  
 IC [6]  
 ICM: C12P021-04  
 ICS: C07K016-00; C07H021-04  
 EXP 536/23.1; 536/23.4; 530/387.1; 530/387.3; 530/387.7; 530/388.1;  
 530/388.8; 530/388.85; 435/69.7; 435/70.21; 435/172.1; 435/172.3  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 41 OF 52 USPTFULT  
 AN 1998:64956 USPTFULT  
 TI Immunogenic cancer proteins and peptides and methods of use  
 IN Calenoff, Emanuel, Chicago, IL, United States  
 PA Northwestern University, Evanston, IL, United States (U.S. corporation)  
 PI US 5763164 19980809  
 RI US 1994-191338 19940203 (8)  
 RLI Continuation-in-part of Ser. No. US 1993-49698, filed on 16 Apr 1993,  
 now abandoned

DT Utility  
 FS Granted  
 LN.CNT 2928  
 INCL INCLM: 435/006.000  
 INCLS: 435/005.000; 435/007.100; 435/007.200; 435/007.900; 435/069.100;  
 530/300.000; 530/388.100; 530/387.200; 530/350.000; 530/333.000;  
 530/403.000; 436/500.000; 436/548.000; 436/818.000; 424/001.110;  
 536/023.100  
 NCL NCLM: 435/006.000  
 NCLS: 424/001.110; 435/005.000; 435/007.100; 435/007.200; 435/007.900;  
 436/069.100; 436/500.000; 436/548.000; 436/818.000; 530/300.000;  
 530/333.000; 530/350.000; 530/387.200; 530/388.100; 530/403.000;  
 536/023.100  
 IC [6]

ICM: C12N001-68  
 ICS: G01N033-53; C07K015-28; C07H021-02  
 EXP 435/6; 435/5; 435/7.1-7.9; 435/69.1; 530/300; 530/388.1; 530/350;  
 530/387.2; 530/333; 530/403; 436/500; 436/548; 436/818; 424/1.11  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 42 OF 52 USPTFULT  
 AN 1998:61155 USPTFULT  
 TI Immunotherapeutic strategies for the treatment of cancer  
 IN Cohen, Edward P., Chicago, IL, United States  
 PA Research Corporation Technologies, Inc., Tucson, AZ, United States (U.S.  
 corporation)  
 PI US 5759535 19980602  
 RI US 1994-242405 19940513 (8)  
 RLI Utility  
 FS Granted  
 LN.CNT 963  
 INCL INCLM: 424/093.210  
 INCLS: 435/172.300; 435/069.100; 435/320.100  
 NCL NCLM: 424/093.210  
 NCLS: 435/069.100; 435/320.100  
 IC [6]  
 ICM: A61K048-00  
 ICS: 514/44; 514/7; 435/172.3; 435/172.1; 435/240.1; 435/240.2; 435/320.1;  
 435/91.1; 424/93.21; 536/22.1; 536/23.1; 536/24.1  
 EXP 514/44; 514/7; 435/172.3; 435/172.1; 435/240.1; 435/240.2; 435/320.1;  
 435/91.1; 424/93.21; 536/22.1; 536/23.1; 536/24.1  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 43 OF 52 USPTFULT  
 AN 1998:54484 USPTFULT  
 TI Monoclonal antibodies reactive with tumor proliferating cells  
 IN Mordech, Jose, Jose Hernandez 1837, Buenos Aires, Argentina 1426  
 RI De Cerone, Silvia Leis, Simbron 4304, Buenos Aires, Argentina 1417  
 RLI Podajcer, Osvaldo Luis, Ave. du General de Gaulle, Strasbourg, France  
 PI Bravo, Alicia Ines, Sanabria 3287, Buenos Aires, Argentina 1417  
 RI US 5753229 19980519  
 RI US 1994-335573 19941107 (8)  
 RLI Continuation-in-part of Ser. No. US 1994-285545, filed on 3 Aug 1994,  
 now abandoned which is a continuation of Ser. No. US 1994-185752, filed  
 on 21 Jan 1994, now abandoned which is a continuation of Ser. No. US  
 1991-766862, filed on 25 Sep 1991, now abandoned

DT Utility  
 FS Granted  
 LN.CNT 1688  
 INCL INCLM: 424/155.100  
 INCLS: 424/174.100; 435/344.000; 435/070.210; 435/172.100; 530/388.800;  
 530/387.100  
 NCL NCLM: 424/155.100  
 NCLS: 424/174.100; 435/070.210; 435/344.000; 530/387.100; 530/388.800  
 IC [6]  
 ICM: A61K039-395  
 ICS: C12N005-10; C12N005-12; C07K016-30  
 EXP 435/70.21; 435/68.1; 435/172.1; 435/240.27; 435/344; 530/387.1;  
 530/388.8; 424/155.1; 424/174.1  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 44 OF 52 USPTFULT  
 AN 1998:39510 USPTFULT  
 TI Compositions and methods for delivery of genetic material  
 IN Carriano, Richard A., Paoli, PA, United States  
 PI Wang, Bin, Beijing, China  
 RI Weiner, David B., Merion, PA, United States  
 RLI Apollon, Inc., Malvern, PA, United States (U.S. corporation)  
 PI The Trustees of the University of Pennsylvania, Philadelphia, PA, United  
 States (U.S. corporation)

PI US 5739118 19980414  
AI US 1994-221579 19940401 (8)  
DT Utility  
FS Granted  
LN CNT 3405  
INCL INCLM: 514/044.000  
INCLS: 514/025.000; 514/027.000; 514/033.000; 514/035.000; 514/054.000;  
514/510.000; 514/580.000; 514/731.000; 514/732.000; 435/375.000;  
435/069.100; 435/069.300; 435/172.100; 435/172.300; 424/278.100;  
424/184.100  
NCLM: 514/044.000  
NCLS: 424/184.100; 424/278.100; 435/069.100; 435/069.300; 435/375.000;  
514/025.000; 514/027.000; 514/033.000; 514/035.000; 514/054.000;  
514/510.000; 514/580.000; 514/731.000; 514/732.000  
IC [6]  
ICM: A61K048-00  
ICS: C07H015-24; C12N015-64; C12N015-87  
EXF 435/172.3; 435/69.1; 435/69.3; 435/375; 435/377; 514/44; 514/33; 514/35;  
514/171; 514/27; 514/54; 514/510; 514/680; 514/731; 514/732; 514/25;  
514/26; 424/278.1; 424/184.1; 935/52; 935/55; 935/56; 536/23.1;  
536/23.5; 536/23.7; 536/23.72; 536/24.5  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 45 OF 52 CAPLUS COPYRIGHT 2002 ACS  
AN 1997:499063 CAPLUS  
DN 127:160563  
TI Cellular proto-oncogene immunogens for cancer vaccines  
IN Halpern, Michael S.; England, James W.  
PA Allegheny University of the Health Sciences, USA; Halpern, Michael S.;  
England, James W.  
SO PCT Int. Appl., 81 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9725860	A1	19970724	WO 1997-US582	19970113
W: AL, AM, AT, AU, AZ, BA, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM	AA	19970724	CA 1997-2241952	19970113
CA 2341952	AI	19970811	AU 1997-16992	19970113
AU 9716992	B2	20000323	EP 1997-902934	19970113
AU 9717356	A1	19990623		
EP 923284	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			

JP 2001501909 T2 20010213 JP 1997-526124 19970113  
US 6365151 B1 20020402 US 1998-167322 19981007  
PRAI US 1996-10262P P 19960119  
WO 1997-US582 W 19970113  
US 1998-101226 B2 19980702

L13 ANSWER 46 OF 52 USPATFILL  
AN 97:3820 USPATFILL  
TI Genetic Immunization  
IN Weiner, David B.; Merton, PA, United States  
Williams, William V.; Havertown, PA, United States  
Wang, Bin, Havertown, PA, United States

PA The Wistar Institute, Philadelphia, PA, United States (U.S. corporation)  
The Trustees of the University of Pennsylvania, Philadelphia, PA, United States (U.S. corporation)  
PI US 5593972 19970114  
AI US 1993-125012 19930921 (8)  
RLI Continuation-in-part of Ser. No. US 1993-29336, filed on 11 Mar 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-8342, filed on 26 Jan 1993, now abandoned  
DT Utility  
FS Granted  
LN CNT 3611  
INCL INCLM: 514/044.000  
INCLS: 424/278.100; 514/615.000; 514/818.000  
NCLM: 514/044.000  
NCLS: 424/278.100; 514/615.000; 514/818.000  
IC [6]  
ICM: A61K045-05  
ICS: A61K048-00; A61K031-00  
EXF 435/320.1; 424/93.1; 424/93.2; 424/93.21; 424/278.1; 514/44; 514/615; 514/818  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 47 OF 52 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.  
AN 97064461 EMBASE  
DN 1997064461  
TI Biological principles and clinical development of prostate cancer gene therapy.  
AU Sanda M.G.  
CS Dr. M.G. Sanda, 2916 Taubman Center, University of Michigan, 1500 E Medical Center Dr., Ann Arbor, MI 48109-0310, United States  
SO Seminars in Urologic Oncology, (1997) 15/1 (43-55).  
Refs: 77  
ISSN: 1081-0943 CODEN: SUONFC  
CY United States  
DT Journal: General Review  
FS 016  
022 Human Genetics  
028 Urology and Nephrology  
SL English

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 96437043	A1	19961021	WO 1997-US582	19970113
W: AL, AM, AT, AU, AZ, BA, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM	AA	19961021	CA 1997-2241952	19970113
CA 2341952	AI	19970811	AU 1997-16992	19970113
AU 9716992	B2	20000323	EP 1997-902934	19970113
AU 9717356	A1	19990623		
EP 923284	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			

JP 2001501909 T2 20010213 JP 1997-526124 19970113  
US 6365151 B1 20020402 US 1998-167322 19981007  
PRAI US 1996-10262P P 19960119  
WO 1997-US582 W 19970113  
US 1998-101226 B2 19980702

L13 ANSWER 48 OF 52 MEDLINE  
AN 96437043 MEDLINE  
DN 96437043 PubMed ID: 8839859  
TI Establishment and characterization of a primary effusion (body cavity-based) lymphoma cell line (BC-3) harboring Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in the absence of Epstein-Barr virus.  
AU Arvanitakis L; Meeri E A; Nador R G; Said J W; Asch A S; Knowles D M; Cesarman E  
CS Department of Pathology, New York Hospital-Cornell Medical Center, New York 10021, USA.  
YORK 10021, USA.  
NC A139192 (NIAID)  
CA42710 (NCI)  
EY06337 (NEI)

SO BLOOD, (1996 Oct 1) 88 (7) 2648-54.  
Journal code: 7603509. ISSN: 0006-4971.  
CY United States  
DT Journal: Article; (JOURNAL ARTICLE)  
LA English  
FS Abridged Index Medicus Journals; Priority Journals; AIDS  
EM 199611  
Entered STN: 19961219

Last Updated on STN: 19980206  
Entered Medline: 19961107

L13 ANSWER 49 OF 52 USPATFILL  
AN 94:86325 USPATFILL  
TI Myod regulatory region  
IN Tapscott, Stephen J., Seattle, WA, United States  
Weintroub, Harold M., Seattle, WA, United States  
Palmer, Theodore D., Kirkland, WA, United States  
Fred Hutchinson Cancer Research Center, Seattle, WA, United States (U.S. corporation)  
PI US 5352595 19941004  
AI US 1991-753520 19910903 (7)  
DT Utility  
FS Granted  
LN.CNT 1777  
INCL INCLM: 435/172.300  
INCLS: 435/240.200; 435/320.100; 536/024.100  
NCLM: 435/006.000  
NCLS: 435/320.100; 435/325.000; 435/354.000; 435/357.000; 435/456.000; 536/024.100  
IC [5]  
ICM: C12N005-10  
ICS: C12N015-11; C12N015-85  
EXF 435/172.3; 435/240.2; 435/320.1; 536/27; 536/24.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L13 ANSWER 50 OF 52 USPATFILL  
AN 93:35475 USPATFILL  
TI Non-malignant cells coupled to adjuvants and their use in a method to induce anti-tumor immunity  
IN Eggers, Arnold E., New York, NY, United States  
PA State University of New York (Suny), Albany, NY, United States (U.S. corporation)  
PI US 5208022 19930504  
AI US 1990-627555 19901210 (7)  
RLI Continuation of Ser. No. US 1988-196037, filed on 19 May 1988, now abandoned  
DT Utility  
FS Granted  
LN.CNT 600  
INCL INCLM: 424/088.000  
INCLS: 424/089.000; 424/090.000; 424/091.000; 424/092.000; 424/093.000; 530/402.000; 530/403.000; 530/404.000; 530/405.000; 530/406.000; 532/002.000; 435/240.100  
NCLM: 424/194.100  
NCLS: 424/184.100; 424/193.100; 424/278.100; 424/279.100; 424/282.100; 435/357.000; 435/366.000; 512/002.000; 530/402.000; 530/403.000; 530/404.000; 530/405.000; 530/406.000  
IC [5]  
ICM: A61K039-00  
ICS: A61K037-02  
EXF 424/88; 424/95; 424/90; 424/91; 424/92; 424/93; 530/402; 530/403; 530/404; 530/405; 530/406; 514/2; 435/240.1  
L13 ANSWER 51 OF 52 MEDLINE  
AN 92394695 MEDLINE  
DN 92394695 Pubmed ID: 1521919  
TI The H-ras oncogene regulates expression of 70- and 45-kDa cell-surface molecules whose expression correlates with tumor-cell immunogenicity.  
AU Copas J; Ehrlich T; Cohen O; Wisnialak O; Tainsky M A; Segal S; Rager-Zieman B; Isakov N  
CS Department of Microbiology and Immunology, Faculty of Health Sciences,

Ben-Gurion University of the Negev, Beer-Sheva, Israel.  
SO INTERNATIONAL JOURNAL OF CANCER. (1992 Sep 9) 52 (2) 329-35.  
Journal code: 0042124. ISSN: 0020-7136.  
CY United States  
DT Journal: Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 199210  
ED Entered STN: 19921023  
Last Updated on STN: 19990129  
Entered Medline: 19921013  
L13 ANSWER 52 OF 52 MEDLINE  
AN 89000486 MEDLINE  
DN 89000486 Pubmed ID: 3262364  
TI In vitro malignant progression of cells derived from Abelson murine leukemia virus-induced thymic lymphomas.  
AU Saggiaro D; Zamarchi R; D'Andrea E; Chieco-Bianchi L  
CS Institute of Oncology, University of Padova, Italy.  
SO BRITISH JOURNAL OF CANCER. (1988 Aug) 58 (2) 152-7.  
Journal code: 0370635. ISSN: 0007-0920.  
CY ENGLAND: United Kingdom  
DT Journal: Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 198811  
ED Entered STN: 19900308  
Last Updated on STN: 19970203  
Entered Medline: 19881121

=>